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I. SUMMARY 
 
 
The ErbB family of receptor tyrosine kinases play important role in normal physiological 
processes occurring during development; moreover, their deregulated expression has 
been implicated in human cancer. Cancer patients, whose tumors have alterations in 
ErbB1 or ErbB2, tend to have a more aggressive disease associated with parameters 
predicting a poor clinical outcome, including tumor metastases. For tumors to 
metastasize, the cells have to possess specific characteristics, including the ability to 
migrate and to invade the surrounding basal membrane. The role of the Neu/ErbB2 
receptor in cancer cell migration is the major topic of this thesis. 
The Neu/ErbB2 receptor is often overexpressed in different human tumors, including 
breast and ovarian tumors. Clinical and in vitro studies revealed that Neu/ErbB2 plays 
important functions in tumor cell motility. Upon ErbB receptors activation via ligand-
induced dimerization, receptors autophosphorylate specific tyrosines in the carboxy 
domain leading to activation of downstream signaling cascades, including the mitogen-
activated protein kinase (MAPK) and the phosphatidylinositol-3-kinase (PI3K) pathways. 
These pathways, which are known to be important for cell migration, are involved in 
actin cytoskeleton remodeling, leading to formation of lamellipodia and actin stress 
fibers. 
In this work we used T47D breast carcinoma cells expressing Neu/ErbB2 add-back 
mutants harboring none or only one of the five major autophosphorylation sites, to study 
the contribution of individual Neu/ErbB2 tyrosine autophosphorylation sites in cell 
migration. We showed that activation of MAPK and PI3K in T47D cell failed to induce 
efficient cell motility in the absence of the Neu/ErbB2 tyrosines 1201 or 1227 
phosphorylation. Moreover, we present evidence that efficient, long-term cell migration 
depends upon ongoing transcription and translation. Signaling downstream of tyrosine 
1201 and 1227 is required for de novo synthesis of RNA and protein involved in cell 
migration. Further investigation of the function of these two tyrosines led to the 
identification of a novel protein that specifically interacts with the phosphorylated 
tyrosine 1227. We called this new protein Memo for mediator of ErbB2-driven cell 
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motility. Memo does not bind directly to the phosphorylated tyrosine 1227 of the 
Neu/ErbB2 receptor, but very likely via the adaptor molecule Shc. Memo is required for 
ErbB2-driven breast carcinoma cell migration, because its downregulation leads to 
decreased motility of cells expressing the receptor with the tyrosine 1227. Interestingly, 
we found that Memo is not only required for migration downstream of the ErbB 
receptors, but it may be a general mediator of growth factor-induced breast carcinoma 
cell migration.  
Cell migration is a multistep process and we further defined at which step Memo is 
required. We found that upon Neu/ErbB2 activation, wild type cells, but interestingly 
also Memo-deficient cells form actin stress fibers and extend lamellipodia. However, 
Memo-deficient cells are not able to extend microtubules toward the cell cortex. There is 
increasing evidence that not only the actin cytoskeleton but also the microtubule 
cytoskeleton plays a crucial role for cell migration. For instance, microtubules are 
required for the polarization of the cells and also for the transport of proteins required for 
motility to the cell leading edge. Further studies have to be done to understand the exact 
role of Memo in microtubule outgrowth and its contribution to cell motility. 
In summary, the work presented in the thesis shows the identification of a novel protein, 
Memo, which is required for breast carcinoma cell migration. We propose that Memo 
controls cell motility by transmitting extracellular chemotactic signals to the microtuble 
cytoskeleton.  
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III. INTRODUCTION 
 
 
1. THE ERBB RECEPTOR FAMILY OF RECEPTOR TYROSINE 
KINASES  
Within a multicellular organism, cells are continuously exposed to a flow of different 
signals coming from the environment and from the neighboring cells. These signals have 
to cross the membrane and to be converted into intracellular signals in order to be 
correctly interpreted and to exert their pleiotropic effects. During evolution different 
devices have been developed in order to achieve this challenge. One of these is the 
presence of receptors on the surface of the cells, which are responsible for the capture of 
the signals. One class of receptors is the family of receptor tyrosine kinases (RTKs) that 
can be divided in different subfamilies, based on the sequence homologies and conserved 
structural features. The subfamily I is formed by the ErbB or epidermal growth factor 
(EGF) receptors and include four members: EGFR/ErbB1/HER1, ErbB2/Neu/HER2, 
ErbB3/HER3 and ErbB4/HER4. All members have in common a cysteine-rich 
extracellular ligand binding domain, a single hydrophobic transmembrane region and a 
cytoplasmic tail containing tyrosine kinase activity (Ullrich and Schlessinger, 1990). The 
signal-transducing tyrosine kinase activity of these receptors is inactive when they are in 
isolation. A number of different ligands activate the receptor by binding to the 
extracellular domain and inducing the formation of receptor homo- and heterodimers. 
Tyrosine residues on the receptors are cross- or autophosphorylated and serve as docking 
sites for signaling complexes which will then activate different signal transduction 
cascades (Olayioye et al., 2000; Yarden and Sliwkowski, 2001). 
 
 
1.1. ErbB receptors in evolution 
The EGFR signaling module has been highly conserved in evolution. In the nematode 
Caenorhabditis elegans, only one receptor, LET-2, and one ligand, LIN-3, are present 
(Aroian et al., 1990; Hill and Sternberg, 1992). This pathway plays a central during 
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development role in the determination of the fate of several types of cells. The first 
function identified was in vulval induction, which occurs when the LIN-3 ligand secreted 
by an anchor cell binds to LET-23 receptor on adjacent multipotent vulval precursor 
cells. These cells will assume a vulval fate, while the surrounding cells that did not 
receive the LET-23 activation will become part of the epidermis (Chang and Sternberg, 
1999).  
In the fruitfly Drosophila Melanogaster, while only one receptor, DER is present, the 
number of ligands is increased to five (Livneh et al., 1985). DER plays a multitude of 
roles during development, leading to a multitude of cell fate choices: cell division, cell 
survival or cell migration (Schweitzer and Shilo, 1997; Shilo, 2003). To ensure a tight 
activation of these processes, four activating ligands, Spitz (Rutledge et al., 1992), Keren 
(Reich and Shilo, 2002), Gurken (Neuman-Silberberg and Schupbach, 1993) and Vein 
(Schnepp et al., 1996), in conjunction with a negative-feedback loop generated by the 
inhibitory secreted ligand Argos  are present in the fly (Golembo et al., 1996).  
The four mammalian ErbB family members can be activated by multiple ligands, 
providing a higher specificity and expanded repertoire of potential responses, via the 
formation of various homo- or heterodimers. The ErbB receptors are expressed in a 
variety of tissues of epithelial, mesenchymal and neural origin and they play important 
roles during development in cell proliferation, differentiation and migration. In addition, 
deregulated expression of the receptors, especially of ErbB1 and ErbB2, is implicated in 
the formation of human cancers and is associated with an aggressive disease phenotype 
(Slamon et al., 1987; Hynes and Stern, 1994). 
 
 
1.2. ErbB receptor ligands 
In mammals, ErbB receptors are activated by a large family of ligands called EGF-related 
peptides (Riese and Stern, 1998). The structural motif shared by all ligands is the EGF-
like domain composed of six characteristically spaced cysteines, which will form three 
disulfide-linked bridges. This domain function as a receptor binding site and is alone 
sufficient for high affinity binding (Peles et al., 1993; Jones et al., 1999b). Most EGF-
related peptides are synthesized as transmembrane precursors that have to be 
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proteolitically cleaved in order to release the soluble form (Massague and Pandiella, 
1993). In mammals, it was shown that the ADAM (a disintegrin-like and 
metalloproteinase-containing protein) family of zinc proteases, endowed with 
metalloproteinase and disintegrin receptor-binding activity, are involved in the shedding 
of the membrane-anchored precursor form (Gee and Knowlden, 2003; Seals and 
Courtneidge, 2003). Moreover, other studies provide evidence that the matrix 
metalloproteinases MMP-3 and MMP-7 are able to cleave the precursor form of HB-EGF 
(Suzuki et al., 1997; Yu et al., 2002). Interestingly, in Drosophila melanogaster, three of 
the five DER ligands, Spitz, Keren and Gurken are also produced as transmembrane 
precursor molecules. Processing of these molecules is not carried out by 
metalloproteinases like the ADAMs, but by Rhomboids, which are seven-transmembrane 
serine proteases (Urban et al., 2002).  
The mammalian ErbB ligands can be divided into three groups according to the binding 
specificity (Figure 1).  
 
 
Figure 1: Binding specificity of the EGF-related peptide growth factors. 
 
The first group comprises EGF, TGF-α and amphiregulin (AR), which specifically bind 
to ErbB1 (Harris et al., 2003); the second group includes betacellulin (BTC), heparin-
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binding EGF (HB-EGF) and epiregulin (EPR), which bind both ErbB1 and ErbB4 (Harris 
et al., 2003). The third group comprises the neuregulins (NRGs). This group can be 
further subdivided in two subgroups based upon the binding of the NRG to ErbB3 and 
ErbB4 (NRG-1 and NRG-2) or only to ErbB4 (NRG-3 and NRG-4). The neuregulins are 
encoded by four different genes that can be alternative spliced leading to multiple NRG 
isoforms (Falls, 2003). NRG-1 is also known as neu differentiation factor (NDF), 
heregulin (HRG), acetylcholine receptor-inducing activity (ARIA) or glial growth factor 
(GGF), reflecting the biological system where the ligand was first described (Olayioye et 
al., 2000). Interestingly, despite the large number of ligands identified for ErbB1, ErbB3 
and ErbB4, no direct ligand for ErbB2 has been described yet (Klapper et al., 1999). 
However, results from different studies support the idea that ErbB2 functions mainly in 
complex with the other family members, acting as a co-receptor. Interestingly, ErbB2-
containing heterodimers are formed preferentially (Tzahar et al., 1996; Graus-Porta et al., 
1997) and are the most potent complexes concerning activation of signaling pathways 
(Beerli et al., 1995; Graus-Porta et al., 1995). 
 
 
1.3. ErbB receptor dimerization 
1.3.1. The extracellular domain 
Dimer formation between multiple ErbB family members is a process driven by ligand 
binding to the extracellular domain of the receptors. New data from the crystal structure 
of ErbB1 (Garrett et al., 2002; Ogiso et al., 2002), ErbB2 (Cho et al., 2003; Garrett et al., 
2003) and ErbB3 (Cho and Leahy, 2002) have provided a better understanding of the 
dimerization mechanism (Burgess et al., 2003).  
The ErbB receptor extracellular domain can be subdivided in four distinct subdomains, 
named I, II, III and IV. The subdomains I and III of ErbB1 have been identified as 
important in ligand binding, whereas the subdomain II of each receptor in the dimer 
forms a betahairpin arm and holds the body of the other, leading to a direct receptor–
receptor interaction. Interestingly, in the ErbB1 dimer formed by two 1:1 receptor:ligand 
complexes, the two ligands are distant from each other and bind only a single ErbB 
receptor, thus they are monomeric (Lemmon et al., 1997; Schlessinger, 2000). The 
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structure of ErbB2 reveals an activated conformation similar to that of the ErbB1 when 
complexed with a ligand, where the subdomains I and III are interacting, mimicking the 
bridging of the two domains by bound ligand in activated ErbB1 (Figure 2). Between the 
subdomains II and IV there is no interaction, since in ErbB2 three of the seven conserved 
residues important for stabilization of unactivated ErbB1 receptor are different, 
presumably reducing the strength of this interaction. These studies on the structure of 
ErbB2 explain the inability of the ErbB2 receptor to bind known ligands and why ErbB2 
can interact with other ErbB receptors in the absence of direct ligand binding. 
Interestingly, overexpression especially of ErbB2, appears to force the equilibrium 
toward spontaneous homodimer formation leading to activation in the absence of ligands 
(Samanta et al., 1994). This situation is often present in a variety of human cancers 
(Klapper et al., 2000). 
 
 
 
 
 
 
 
 
Figure 2: Model for NRG-induced heterodimerization of ErbB2 and ErbB3 (Burgess et 
al., 2003). 
 
ErbB3 structure is similar to the one of the inactive ErbB1. ErbB3 has impaired kinase 
activity due to substitutions in the kinase domain (Guy et al., 1994) and therefore, in 
order to signal ErbB3 has to form dimers with the other ErbB receptors. 
 
1.3.2. The intracellular domain 
Although the extracellular domain appears to be responsible for the majority of 
interactions leading to ErbBs dimerization, evidence suggests that the intracellular 
domain plays more than a passive role in dimerization. It was proposed that dimerization 
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of ErbB receptors may be influenced by electrostatic charge distribution near the 
membrane proximal regions and that proper orientation of the receptors is critical for 
dimerization (Murali et al., 1996). Moreover, results from one study proposed that the 
kinase domain is critical for dimerization (Chantry, 1995). 
 
 
1.4. Intracellular signaling 
The specificity and potency of intracellular signals are determined by the identity of the 
ligand and the dimer composition, but mainly by the multiple types of phospho-binding 
proteins that associate with the tail of each ErbB receptor in the dimer.  
Ligand binding drives receptor dimerisation, leading to activation of the intrinsic kinase 
domain and subsequent autophosphorylation of specific tyrosine residues (Lemmon and 
Schlessinger, 1994; Jiang and Hunter, 1999). The identity of the ligand, as well as the 
heterodimer partners, determines which are the sites phosphorylated, and therefore, 
which adaptor proteins bind to the receptors (Olayioye et al., 1998). The association of 
the adaptor molecules with the receptor’s phosphorylated tyrosines occurs through their 
Src-homology 2 (SH2) or phosphotyrosine binding (PTB) domains. Interestingly, the 
amino acid sequence adjacent to the phosphorylated tyrosine is also important for the 
binding of the docking proteins (SH2 domains recognize residues carboxy-terminal to the 
phosphorylated tyrosine, whereas PTB domains the amino-terminal ones) (Pawson and 
Scott, 1997; Yaffe, 2002). The Shc/Grb2-activated mitogen-activated protein kinase 
(MAPK) pathway is a downstream target of all ErbB receptors (Olayioye et al., 2000). 
Interestingly, not only the mammalian ErbB receptors, but also the Drosophila 
homologue DER and the C. elegans homologue Let-23 couple via Shc or Grb2 to the 
MAPK pathway (Diaz-Benjumea and Hafen, 1994; Moghal and Sternberg, 2003). In 
addition, the phosphatidylinosithol-3-kinase (PI3K) pathway is activated by all ErbB 
receptors, however the potency and kinetics of PI3K activation differs among the ErbB 
dimers probably because PI3K couple directly with ErbB3 and ErbB4, but indirectly with 
ErbB1 and ErbB2 (Prigent and Gullick, 1994; Soltoff and Cantley, 1996; Elenius et al., 
1999). Despite sharing some pathways, each receptor is coupled with a distinct set of 
signaling proteins (Table 1) (Olayioye et al., 2000).  
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ERBB1 ERBB2 ERBB3 ERBB4 
Grb2 
(Batzer et al., 1994) 
Grb2 
(Ricci et al., 1995; 
Dankort et al., 1997) 
Grb7 
(Fiddes et al., 1998) 
p85 
(Elenius et al., 1999) 
 
Nck  
(McCarty, 1998) 
Nck 
(Dankort et al., 
2001b) 
Shc 
(Prigent and Gullick, 
1994) 
Shc 
(Cohen et al., 1996) 
Crk  
(Hashimoto et al., 
1998) 
Crk 
(Dankort et al., 
2001b) 
p85 
(Prigent and Gullick, 
1994) 
 
Shc  
(Batzer et al., 1994) 
Shc 
(Ricci et al., 1995; 
Dankort et al., 1997) 
  
Dok-R  
(Jones and Dumont, 
1999) 
Dok-R 
(Dankort et al., 
2001a) 
  
PLCγ  
(Chattopadhyay et al., 
1999) 
p34 
(Dankort et al., 
2001a) 
  
PTB-1B  
(Milarski et al., 1993) 
p150 
(Dankort et al., 
2001a) 
  
SHP-1  
(Keilhack et al., 
1998) 
Chk 
(Zrihan-Licht et al., 
1998) 
  
Src  
(Stover et al., 1995) 
   
Abl  
(Zhu et al., 1994) 
   
Cbl 
(Levkowitz et al., 
1996)  
   
 
Table 1: Signaling proteins that associate directly with the ErbB receptors. 
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The principal process that turns off signaling downstream of the ErbB receptors is ligand-
mediated receptor endocytosis. The kinetics of this process depends on the dimers 
composition. In contrast to the other ErbB receptors, activated ErbB1 is rapidly 
internalized and targeted to lysosomes (Baulida et al., 1996). However, dimerization of 
ErbB1 with ErbB2 decreases the rate of endocytosis (Lenferink et al., 1998; Wiley, 
2003). Recent studies have shown a strong correlation between Cbl mediated 
ubiquitination of ErbB1 and accelerated degradation (Levkowitz et al., 1999; Yokouchi 
et al., 1999). This mechanism of negative regulation of ErbB1 is also present in the 
nematode C. elegans, where sli-1, the homologue of Cbl is involved in LET-23 
degradation (Jongeward et al., 1995). 
 
 
1.5. ErbB receptors crosstalk with other receptors 
The ErbB signaling network integrates not only the input from the multiple EGF-related 
peptides, but also from heterologous signals, such as hormones, neurotransmitters, 
lymphokines and stress inducers (Carpenter, 1999). Many of these transregulatory 
interactions are mediated by protein kinases that directly phosphorylate the ErbB 
receptors affecting their kinase activity or endocytic transport. The most extensively 
studied mechanism involves activation of ErbB by G-protein-coupled receptors (GPCRs) 
(Carpenter, 2000). Different groups showed that GPCR-dependent stimulation of the 
EGF receptor involve stimulation of membrane-bound metalloproteinase, which induce 
the extracellular release of the ErbB1 ligand heparin-bound-EGF (HB-EGF) (Fujiyama et 
al., 2001; Pierce et al., 2001; Asakura et al., 2002). A similar activation could also occur 
for other growth factors, such as the precursor of transforming growth factor-α (pro TGF-
α). This model of receptor tyrosine kinases transactivation is called triple-membrane-
passing-signaling (TMPS) since it involves three signaling steps traversing the membrane 
(Figure 3) (Prenzel et al., 1999; Wallasch et al., 2002). Transactivation by GPCRs has 
been shown for other receptor tyrosine kinases, such as ErbB2 and platelet-derived 
growth factor receptor (PDGF). Moreover, additional pathways of ErbB1 transactivation 
that do not involve activation of metalloproteinases have been identified. It was proposed  
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Figure 3: The triple-membrane-passing-signaling model (Wetzker and Bohmer, 2003). 
 
that the tyrosine kinases Src and Pyk mediate ErbB1 transactivation downstream of 
GPCR activation. Both kinases can interact with ErbB1 and Src is able to directly 
phosphorylate and activate ErbB1 (Luttrell et al., 1996; Biscardi et al., 1999; Keely et al., 
2000). Alternatively, GPCR activation might lead to the production of hydrogen 
peroxide, which inactivates phosphatases that negatively control receptor tyrosine kinase 
activity. 
  
 
1.6. ErbB receptors in mouse development 
The ErbB network is a key developmental signaling pathway throughout evolution. The 
function of specific ligands and individual ErbB receptors in mammalian development 
was studied using knockout and transgenic mice. 
ErbB1 and its ligands: Inactivation of ErbB1 is embryonic or perinatal lethal depending 
on the genetic background (Threadgill et al., 1995). The mice show defects in the 
development of many organs, including lung, skin, brain and gastrointestinal tract 
(Miettinen et al., 1995; Threadgill et al., 1995; Sibilia et al., 1998). Transgenic and in 
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vitro studies reveal a role for ErbB1 in promoting proliferation and differentiation of the 
epithelial component of those organs. Mice lacking transforming growth factor-α (TGF-
α) have abnormal skin, hair and eye development, but in contrast to ErbB1 deficient 
mice, they show no brain abnormalities (Luetteke et al., 1993; Mann et al., 1993). The 
limited phenotype of TGF-α knock out mice suggest that each ErbB ligand has a distinct 
functional role and tissue specificity during development. 
ErbB2, ErbB3, ErbB4 and the neuregulins: Mice defective in ErbB2, ErbB4 and 
NRG-1 die at embryonic day 10.5 due to defect in the cardiac traberculae formation, 
showing the importance of ErbB2/ErbB4 heterodimers in heart development (Gassmann 
et al., 1995; Lee et al., 1995; Meyer and Birchmeier, 1995). Mice lacking ErbB3 survive 
until embryonic day 13.5 and they suffer from valves heart malformation (Erickson et al., 
1997). Interestingly, mice lacking ErbB2, ErbB3 and NRG-1 have underdeveloped 
sympathetic ganglion chain, due probably to defective migration of neuronal progenitors 
from the neuronal crest (Britsch et al., 1998). Moreover, a genetic rescue of ErbB2 knock 
out mice heart development by myocardial expression of ErbB2 cDNA, reveals the 
important role of ErbB2/ErbB3 heterodimers in peripheral nervous system development 
(Woldeyesus et al., 1999). 
 
1.5.1 ErbBs in development of the immature mammary gland  
The mammary gland is an unusual organ because it undergoes postnatal development. In 
fact, female are born with a small ductal tree. Under the influence of systemic hormones, 
extensive ductal elongation and branching occurs at puberty and in adult animals. Further 
development in pregnancy includes continued ductal growth, formation of glandular 
structures and production of milk at parturition. Weaning induces involution, a program 
of cell death and remodeling to restore the gland to a prepregnancy-like state.  
Each ErbB receptor has a unique pattern of expression in this organ. In the mouse, ErbB1 
and ErbB2 are abundant prior to puberty and during subsequent developmental stages, 
whereas ErbB3 and ErbB4 display low levels prior to pregnancy (Schroeder and Lee, 
1998; Sebastian et al., 1998). All four ErbBs are expressed during pregnancy and 
lactation, but ErbB1 and ErbB2 are preferentially expressed in lactating ducts and alveoli, 
whereas ErbB3 and ErbB4 are more pronounced in alveoli (Schroeder and Lee, 1998). 
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ErbB1 and ErbB2 are phosphorylated and therefore active during puberty, late pregnancy 
and lactation (Sebastian et al., 1998). During pregnancy all four receptors are 
phosphorylated (Schroeder and Lee, 1998; Sebastian et al., 1998). These results suggest 
that ErbB1 and ErbB2 act at puberty, late pregnancy and lactation, whereas ErbB3 and 
ErbB4 are most active in pregnancy and lactation. 
Most ErbB1-/- mice die after birth, however the prolonged survival of a fraction of them 
made it possible to determine that they are impaired in postnatal ductal formation 
(Wiesen et al., 1999). These mice have a reduced proliferation of the mammary 
epithelium and stroma and they lose the periductal fibroblasts. 
Comparison of single or combined knockout for EGF, TGF-α and AR showed that AR is 
important for normal ductal development (Luetteke et al., 1999). The severity of the 
phenotype and the lack of a similar phenotype associated with loss of EGF or TGF-α 
identified AR as the foremost mammary regulator of ErbB1 at puberty (Luetteke et al., 
1999; Li et al., 2002). 
 
1.5.2. ErbBs and ErbB ligands in adult mammary gland development 
ErbBs are active during adult mammary development. Transgenic mice expressing a 
truncated dominant negative (DN) ErbB1 receptor under the control of the mammary 
gland specific mouse mammary tumor virus (MMTV) display reduced ductal side 
branching (Xie et al., 1997). Transgenic animals expressing a dominant negative MMTV-
truncated ErbB2 have significant defects in mammary developmental late in gestation 
and early postpartum, with failure of alveolar expansion and production of milk (Jones 
and Stern, 1999). Lactation problems and early postpartum immature phenotype are also 
seen in mice expressing MMTV-DN-ErbB4 (Jones et al., 1999a; Tidcombe et al., 2003). 
ErbB3 is expressed and active during pregnancy, but an ErbB3 loss-of-function 
phenotype in the mammary gland has not been described yet. 
Mammary organ culture experiments have suggested that NRG induces alveolar 
morphogenesis and lactational differentiation (Yang et al., 1995). Targeted disruption of 
NRG1α, but not NRG1β transiently reduces alveolar maturation and proliferation of the 
mammary epithelium late in pregnancy (Li et al., 2002).  
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The limited expression of ligands and activation of ErbB receptors during involution (the 
final developmental step) and the lack of effects on involution in ligands knockout, 
suggests that ErbBs do not contribute significantly to this developmental step. 
 
 
1.7. The ErbB2/Neu receptor 
ErbB2 is the second member of the ErbB family of receptor tyrosine kinases and is often 
overexpressed or amplified in different tumors. The human c-erbB2 gene was isolated 
from human genomic DNA library screened with a viral v-erbB hybridization probes 
under low stringency (Coussens et al., 1985; King et al., 1985; Semba et al., 1985). The 
human c-erbB2 is localized to bands q12-q22 of chromosome 17. Sequence analysis of 
the cDNA confirmed that the c-erbB2 gene was the human homologue of the rat neu and 
had significant homology with the erbB gene (Coussens et al., 1985; Yamamoto et al., 
1986). The extracellular portion of ErbB2 is 44% homologous to ErbB1 (Bargmann et 
al., 1986b) (Figure 4). The kinase domain is highly conserved within the ErbB family, 
whereas the carboxy-terminus residues show the highest sequence variation. 
 
 
Figure 4: Domain homology between ErbB1 and the other ErbB family members. 
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1.7.1 ErbB2 and Neu in cancer 
The rat neu oncogene was originally identified in cell lines derived from rat 
neuroectodermal tumors (Shih et al., 1981). Further studies showed that the neu 
oncogene is associated with a specific antigen designated p185 (Padhy et al., 1982; 
Schechter et al., 1984), a phosphoprotein that is associated to the plasma membrane 
(Padhy et al., 1982; Drebin et al., 1984). The sequence suggested that the normal version 
of p185 is related to erbB. A comparison of cDNA clones isolated from both normal and 
transforming alleles indicates that the difference between the oncogenic and the proto-
oncogenic form of neu is a single (T→A) point mutation resulting in an amino acid 
substitution (Val→Glu) at position 664 within the transmembrane domain of the receptor 
(Bargmann et al., 1986a). Although the oncogenic point mutation identified in the rat neu 
is not found in human tumors, a polymorphism at codon 655 of c-erbB2, which results in 
Val→Ile has been identified (Papewalis et al., 1991) and an association between the 
polymorphism and an increased risk of breast cancer was shown (Xie et al., 2000). The 
human protein is overexpressed in a number of adenocarcinomas as a result of c-erbB2 
gene amplification or protein overexpression. ErbB2 overexpression leads to the 
spontaneous formation of ErbB2 homodimers, which activate different downstream 
signaling pathways. Observation of c-erbB2 amplification was first described in human 
gastric tumors (Yamamoto et al., 1986), but also appears to be associated with non-small 
cell lung (Weiner et al., 1990), colon (Cohen et al., 1989), ovarian (Slamon et al., 1989) 
and pancreatic adenocarcinomas (Williams et al., 1991).  Overexpression of ErbB2 has 
been found in about 30% of invasive breast cancers (Slamon et al., 1987; Slamon et al., 
1989). ErbB2 overexpression correlates with tumor size, spread of the tumor to lymph 
nodes, high grade, high percentage of S-phase cells, aneuploidy and lack of steroid 
hormone receptors, implying that ErbB2 confers a strong proliferative advantage to tumor 
cells (Ross and Fletcher, 1998). Moreover, ErbB2 overexpression is associated with 
resistance to anti-estrogen therapy and poor patient prognosis (Borg et al., 1994). 
 
1.7.2. Role of ErbB2 in tumor and metastases formation  
Tumorigenesis is a multistep process that drives the progressive transformation of normal 
cells into highly malignant derivatives. During this progression the cells have to gain new 
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properties necessary for the malignant phenotype (Hanahan and Weinberg, 2000; Sledge 
and Miller, 2003). First, cancer cells have to acquire a proliferative potential that allow 
them to grow continuously and independently of growth signals. Moreover, the cells have 
to become insensitive to antiproliferative signals and should evade apoptosis. In addition, 
new blood vessels have to be formed in order to supply the tumor with oxygen and 
nutrients. The final step, metastases formation, is dependent on the capability of the cells 
to migrate and invade the surrounding tissue. ErbB receptors, as well as ErbB ligands, 
play distinct roles in each of these processes (Evan and Vousden, 2001; Green and Evan, 
2002; Holbro et al., 2003). 
Different studies have been done in order to better understand the role of the ErbB 
receptors in cell proliferation, angiogenesis and cell motility (Holbro et al., 2003). Since 
the central topic of this thesis is the role of ErbB2 in cell migration, only this aspect will 
be discussed in more details although if the knowledge is very limited. 
Studies with transgenic mice have revealed that mice bearing either an activated form of 
Neu (NeuT or c-Neu with mutations in the extracellular region proximal to the 
transmembrane domain) or the wild type proto-oncogene under the control of the mouse 
mammary tumor virus (MMTV) promotor, frequently develop mammary tumors and 
lung metastases (Muller et al., 1988; Bouchard et al., 1989; Guy et al., 1992; Siegel et 
al., 1994; Siegel et al., 1999). Metastases formation is very rapid in mice expressing the 
activated neu receptor, whereas the ones expressing the wild type proto-oncogene form 
metastasis only after a long latency. More studies using NeuT add-back mutants (mutants 
which have only one single tyrosine autophosphorylation site) were performed in order to 
better understand the role of the adaptor molecules, binding to specific NeuT sites, in 
cancer development and metastases formation (Dankort et al., 2001b). Interestingly, two 
mice strains expressing only the second or the forth of the five add-back mutants 
efficiently form mammary tumors, but only one of them develops lung metastases, 
suggesting that metastases formation is more complex than tumor formation. 
In vitro studies reveal that many types of tumor cells migrate or scatter in response to 
autocrine receptor activation (El-Obeid et al., 1997) or ErbB ligands treatment 
(Adelsman et al., 1999; Chausovsky et al., 2000; Spencer et al., 2000). Moreover, not 
only ErbB2 activation via a ligand but also ErbB2 overexpression is correlated with 
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increased cell motility and invasion by alterations in cell and cytoskeletal morphologies 
(De Corte et al., 1994; Adam et al., 1998; Grothey et al., 2000). 
In order to form metastases, carcinoma cells have to leave the primary tumor, process 
dependent on the ability of the cells to migrate. Afterward, they invade the surrounding 
basal membrane, process dependent on proteolysis, in order to reach and invade the blood 
vessels. Once in the blood, tumor cells circulate and they become trapped in the capillary 
of distant organs. At this point the cells will leave the blood stream and migrate into the 
organ. The cells start to proliferate in the target organ, forming the secondary tumor 
(Fidler, 2003). In vitro, HRG treatment of breast cancer cells was shown to induce the 
expression of the matrix metalloproteinase (MMP)-9 (Xu et al., 1997) and of the 
membrane associated urokinase-type plasminogen activator (uPA) and its receptor 
(Mazumdar et al., 2001), leading to an invasive phenotype. Clinical studies reveal that 
expression of MMP-2 and MMP-9 is associated with grade and stage of breast cancer 
(Monteagudo et al., 1990; Zucker et al., 1993; Kossakowska et al., 1996). Moreover, 
uPA expression and the ratio of uPA to the plasminogen activator inhibitor-1 (PAI-1) are 
associated with impaired survival and local relapse (Prechtl et al., 2000; Harbeck et al., 
2002). Inhibitors of MMP and uPA may have therapeutical potential, but clinical 
development has so far been limited due to toxicity (Bramhall et al., 2001; Hidalgo and 
Eckhardt, 2001; Shepherd et al., 2002). 
 
 
1.8. ErbB as target for cancer therapy 
The central role of ErbB2, but also of ErbB1 in the development of solid tumors and the 
detailed understanding of the underlying biochemistry has made the ErbB network a 
target for pharmacological intervention. Many different approaches have been taken.  
Immunological strategies: a humanized monoclonal antibody to ErbB2 (Herceptin) 
(Hudziak et al., 1989) has been approved for clinical use, both alone and in combination 
with chemotherapeutic agents (Baselga et al., 1998; Pegram et al., 1999). Herceptin 
induces ErbB2 downregulation and a proliferative block of the cells via induction of the 
cyclin-dependent kinase inhibitor p27Kip1 and the Rb-related protein p130 (Sliwkowski et 
al., 1999; Lane et al., 2000; Yakes et al., 2002). Furthermore, it has been shown that in 
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vivo, Herceptin elicits an antibody-mediated cytotoxicity through engagement of Fc 
receptors and that this process contributes to its anti-tumor activity (Clynes et al., 2000). 
The anti-tumor properties of Herceptin used alone and its increased efficacy when used in 
combination with cytotoxic agents have been confirmed using in vivo xenograft models 
(Baselga et al., 1998; Pegram et al., 1999). 
In vitro approaches: One way it is to block transcription or translation by triple-forming 
oligonucleotides, designer transcription factor, antisense oligonucleotides or specific 
ribozymes (Ebbinghaus et al., 1993; Noonberg et al., 1994; Juhl et al., 1997; Beerli et al., 
2000; Chiang et al., 2000; Roh et al., 2000). Another way is to interfere with the 
trafficking of the receptors to the cell surface using intracellular single-chain Fv 
fragments of antibodies (scFvs) (Beerli et al., 1994; Neve et al., 2000). An alternative 
approach is to affect receptor stability with e.g. geldanamycin (Basso et al., 2002). 
However for clinical use, the most promising and advanced strategies include reversible 
and irreversible low molecular weight inhibitors that compete with ATP in the receptor 
kinase domain. Inhibitors capable of discriminating between ErbB receptors and other 
kinases have been developed (Fry et al., 1998). The irreversible inhibitors bind to a 
conserved cysteine in the ATP-pocket, increasing selectivity of the inhibitor (Fry, 2003). 
At least five of these compounds are now being tested in human clinical studies (Baselga, 
2002; Khalil et al., 2003). 
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2. CELL MIGRATION 
Cell migration plays a central role in the development and maintenance of multicellular 
organisms. In embryogenesis, cellular migration is very important in morphogenic 
processes ranging from gastrulation to development of the nervous system (Locascio and 
Nieto 2001). However, migration is also essential in the adult organism for normal 
physiological processes as well as pathological ones (Locascio and Nieto, 2001; Franz et 
al., 2002). For example, during inflammation leukocytes have to migrate to the area of 
interest, where they mediate phagocytic and immune functions. Migration of fibroblasts 
and vascular endothelial cells is required during wound healing. In metastasis, tumor cells 
migrate from the initial tumor mass into the blood stream, which they will leave and 
finally migrate into the new site. 
 
 
2.1. The motility cycle of a cell 
Migration of cells over a substratum requires the coordination of several cellular 
processes which operate in a cycle. This cycle can be divided into five different steps 
(Figure 5): 
1. Extension of the leading edge 
2. Adhesion to the matrix  
3. Contraction of the cell body 
4. Release from the contact sites 
5. Recycling of the membrane receptors from the rear to the front of the cell 
Each of these steps is dependent upon one or more biochemical processes, which include 
protein and enzymatic components, extracellular-matrix receptors on the cell and 
physical forces. 
 
1. Extension of the leading edge: the critical element of the extension process is directed 
actin assembly (Cramer et al., 1994). The process of actin assembly must generate a 
protrusive force sufficient to extend the plasma membrane against compressive forces 
imposed by the environment, and by tension within the plasma membrane. The 
extensions formed are of two different types: flat, broad, sheet-like structures, called 
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lamellipodia, or thin, cylindrical, needle-like projections called filopodia. Cytoplasmic 
organelles are excluded from both of these structures, which contain actin and actin-
associated proteins (Schmidt et al., 1993). 
 
Figure 5: The five steps model of cell migration (Lauffenburger and Horwitz, 1996). 
 
2. Adhesion to the matrix: extension of the leading edge to new extracellular matrix 
(ECM) molecules will enable receptors to bind and to initiate the adhesion process. The 
adhesion receptors-ECM complexes stabilize newly extended cellular domains and 
permit the cell to exert forces on the substrate. At the molecular level, integrins are the 
best characterized receptors for ECM molecules playing a role in cell migration (Holly et 
al., 2000). Integrins are a family of heterodimeric transmembrane adhesion receptors that 
link ECM on the outside of the cell with the cell’s cytoskeleton (Hynes, 1992). 
Covalent modification of proteins by tyrosine phosphorylation is strongly implicated in 
the formation of adhesive structures. Upon adhesion to a substratum, a group of 
cytoskeletal-associated proteins are phosphorylated on tyrosines: focal adhesion kinase 
(FAK), paxillin and tensin are among the prominent and best characterized of these 
phosphoproteins that form the adhesive complexes (Lo et al., 1994; Schaller and Parsons, 
1994; Turner, 1994).  
Moreover, also members of the Rho GTPases are important in the formation of new 
adhesions and stabilization of existing ones (Hall, 1998). Rac and Cdc42 appear to be 
important in the formation of new protrusions and small focal complexes, required for 
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adhesion at the cell periphery. Rho induces the maturation of the small focal complexes 
into the larger and highly organized focal adhesions. 
Microtubules are regulators of focal adhesion and focal complex dynamics (Kaverina et 
al., 1999; Waterman-Storer and Salmon, 1999). Depolymerization of microtubules leads 
to a decrease in the turnover of focal complexes, which results in reduced cell spreading 
and formation of large peripheral focal adhesions. Adhesions dissociate upon direct 
contact with microtubules and the cell either retracts the edge or forms new protrusions. 
Thus, microtubules appear to regulate the turnover of focal adhesions by targeting them 
directly and delivering signals to promote their turnover, initiating either protrusion or 
retraction (Palazzo and Gundersen, 2002). 
 
3. Contraction of the cell body: at least two distinct types of force have to be generated 
independently by a motile cell. The first is the protrusive force required to extend 
membrane processes, lamellipodia and filopodia. Generation of this force is dependent on 
actin polymerization and not on myosin motor activity. The second force is a contractile 
force, needed to move the cell body forward. This force is dependent on active myosin-
based motors (Cramer, 1999; Katoh et al., 2001). Rac and Cdc42 appear to be important 
in regulating the contractile forces at the leading edge by modulating phosphorylation of 
the myosin light chain (MLC) (Bagrodia and Cerione, 1999) (Figure 5). 
 
 
Figure 5: Regulation of the contractile forces dependent on MLC. 
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 Phosphorylation of MLC by myosin light chain kinase (MLCK) promotes both their 
dimerization and their interaction with actin to drive contraction. Rho regulates the 
organization of actin into bundles, called stress fibers. Rho promotes tension through its 
action on MLC phosphorylation (Katoh et al., 2001). However, in this case, Rho activates 
Rho kinase, which in turn inhibits the myosin phosphates, maintaining MLCs in a 
contractile state. The resulting contractile forces organize the actin in fibers and cluster 
the integrins, leading to tightly bundled actin and focal adhesions. It appears that Rho 
kinase requires Dia proteins, members of formin homology family, for proper formation 
of stress fibers (Nakano et al., 1999; Watanabe et al., 1999). Dia may contribute to stress 
fibers formation through interaction with profilin, a G-actin binding protein which 
promote actin polymerization and organization of actin filaments into stress fibers 
(Watanabe et al., 1997; Alberts, 2001). 
 
4. Release from the contact sites: upon cell body contraction, an asymmetry in the 
adhesion process has to be generated for forward migration. At the cell rear, adhesions 
need to be released, whereas at the front the formation of adhesion has to be controlled. 
Focal contact disassembly occurs through several mechanisms. Actin binding and 
severing proteins such as gelsolin and cofilin, cap actin filaments and cause actin filament 
breakage, thereby promoting filament turnover (Wear et al., 2000). Phosphatases play 
important roles in rear release, for example by limiting the assembly of cytoskeletal 
proteins (Zeng et al., 2003). Migratory defects have been reported in cells lacking Src 
family kinases (Klinghoffer et al., 1999), FAK (Ilic et al., 1995; Sieg et al., 1999) and 
calpain (Huttenlocher et al., 1997), all focal adhesion components. The defects appear to 
be caused by an inhibition of focal adhesion turnover, because focal adhesion formation 
is not impaired. Moreover, focal contacts are further weakened through the proteolytic 
cleavage of adhesion receptors by sheddases (Moss and Lambert, 2002) and the 
accumulation of collagen fragments that are generated while the cell moves forward 
(Carragher et al., 1999). 
 
5. Recycling of membrane receptors: in order to maintain a continuous retrograde flow 
of integrins on the cell surface, migrating cells must reload receptor at the leading edge. 
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Two different models have been suggested to explain the recycling of these proteins. 
Integrins detach from the substrate and become internalized via the endocytic vesicles 
and transported toward the leading edge (Bretscher, 1996), or there is a forward transport 
of the protein in the plasma membrane (Kucik et al., 1989; Sheetz et al., 1990; Regen and 
Horwitz, 1992).  
 
 
2.2. The Rho GTPases: Rho, Rac and Cdc42 
Rho GTPases regulate many important processes in eukaryotic cells. They are principally 
known for their role in regulating the actin cytoskeleton organization, but they also 
participate in the regulation of cell polarity, microtubule dynamics, vesicular transport 
pathways and gene transcription (Etienne-Manneville and Hall, 2002). 
Rho GTPases cycle between an active GTP-bound conformation and an inactive GDP-
bound conformation. Guanine nucleotide exchange factors (GEFs) enhance the exchange 
of bound GDP for GTP, whereas GTPase-activating proteins (GAPs) increase the 
intrinsic rate of hydrolysis of bound GTP. In addition, the Rho GTPases are regulated 
further by guanine nucleotide dissociation inhibitors (GDIs), which can both inhibit 
exchange of GTP and hydrolysis of bound GTP preventing the interaction of the Rho 
GTPases with the plasma membrane. In the GTP-bound form they interact with 
downstream target proteins to induce cellular responses (Schmitz et al., 2000).  
The Rho GTPases Rho, Rac and Cdc42 regulate actin cytoskeleton polymerization, 
depolymerization and the activity of actin-associated myosins. These regulatory proteins 
are part of a hierarchical signaling cascade that initiate the formation of filopodia, 
lamellipodia, focal adhesion and stress fibers (Hall, 1998). Formation of filopodia and 
induction of polarization are regulated by Cdc42 (Kozma et al., 1995; Nobes and Hall, 
1995), while formation of lamellipodia and small adhesions is regulated by Rac, whose 
activation stimulates also membrane ruffling (Ridley et al., 1992). Finally formation of 
actin stress fibers and of focal adhesion, highly organized adhesive complexes containing 
termini of stress fibers, is regulated by Rho (Ridley and Hall, 1992). 
Moreover, recent evidence indicates that Rho GTPases might also affect the organization 
of microtubules (Waterman-Storer et al., 1999). It was shown that Rac activation 
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promotes growth of microtubules (Wittmann et al., 2003). Interestingly, previous work 
provide evidence that microtubule polymerization induces Rac activation (Waterman-
Storer et al., 1999). These results suggest that Rac and microtubules might constitute a 
positive feedback loop in which microtubules promote Rac activation, and Rac induces 
further microtubule growth reinforcing the polarization of migrating cells. Moreover, not 
only Rac, but also Cdc42 activation can mediate polarization of the microtubule network 
in migrating cells (Nobes and Hall, 1999). Microtubule depolymerization induces 
multiple cell morphological changes that include actin stress fiber formation and focal 
adhesion assembly, effects dependent on Rho activity (Liu et al., 1998; Krendel et al., 
2002). Further investigations reveal that microtubule depolymerization in fact, induces 
activation of Rho.  
 
 
2.3. The actin cytoskeleton in lamellipodia formation 
Actin and actin-related proteins (Arps) are major determinants of cell morphology in 
eukaryotic, but also prokaryotic cells. Assembly of actin filaments drives the locomotion 
of many cell types including nerve growth cones, fibroblasts and leukocytes. Expansion 
of a dense network of actin filaments underlying the plasma membrane provides 
sufficient force to push forward the leading edge (Svitkina et al., 1997). Actin 
polymerization also moves some cytoplasmic particles including endosomes (Merrifield 
et al., 1999), pathogenic bacteria and viruses (Dramsi and Cossart, 1998), as well as drive 
engulfment during phagocytosis (Aderem and Underhill, 1999; Chimini and Chavrier, 
2000). 
The actin filaments are double helical polymers of globular subunits all arranged head-to 
tail to give the filament molecular polarity. One end is called the barbed end and the other 
the pointed end. The barbed end is favored for growth and actin filaments in cells are 
strongly oriented with respect to the cell surface, barbed end outward (Small et al., 1978).  
Actin-based cellular motility can be explained by the treadmilling-type reaction (Figure 
6). The actin-monomer-binding protein profilin and, in eukaryotic cells, sequestering 
proteins such as thymosin-β4 maintain a pool of unpolarized ATP-actin subunits in the 
cells (Goldschmidt-Clermont et al., 1992; Vinson et al., 1998). Extracellular stimuli such 
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as chemotactic factors bind to the plasma membrane receptors activating intracellular 
signaling molecules including the Rho GTPases (Van Aelst and D'Souza-Schorey, 1997; 
Schmitz et al., 2000). Cdc42 binds and activates WASP/Scar family proteins, which are 
nucleation-promoting factors, by freeing them from autoinhibition (Bishop and Hall, 
2000; Higgs and Pollard, 2001; Ridley, 2001). Active WASP/Scar proteins bring together 
an actin monomer and an Arp2/3 complex (Machesky et al., 1999; Yarar et al., 1999; 
Higgs and Pollard, 2001), an assembly of seven subunits including two actin-related 
proteins (Arp2 and Arp3) (Machesky et al., 1994). The Arp2/3 complex sits on the 
“mother” filament and initiates the growth of a new “daughter” filament, polymerizing 
out from it at an angle of 70º (Mullins et al., 1998; Amann and Pollard, 2001). The new 
branch grows rapidly at its barbed end by addition of actin-profilin complexes stored in 
the cytoplasm. As it grows, it pushes the plasma membrane and the cell forward.  
 
 
Figure 6: Treadmilling model for protrusion formation at the leading edge (Pollard and 
Borisy, 2003). 
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The system is set up to terminate the growth of the filaments automatically, before they 
grow so long that they do not push effectively. Then, the network dissociate so that the 
components can be recycled for the next step of polymerization. First of all, the new 
filament is capped by capping proteins, terminating, therefore, the elongation step (Sun et 
al., 1999; Cooper and Schafer, 2000). Next, small proteins called actin-depolymerization 
factors (ADF)/cofilin bind to ADP-Pi-actin filaments and accelerate the dissociation of 
the gamma phosphate (Bamburg et al., 1999). Dissociation of phosphate promotes 
dissociation of branches from Arp2/3 complexes and binding of ADF/cofilin to ADP-
actin subunits. ADF/cofilin bound to filaments promotes severing of the filaments and 
dissociation of ADP-actin bound to ADF-cofilin (Blanchoin et al., 2000). Moreover, Rho 
family GTPases activate p21-activated protein kinase (PAK) or Rho-associated kinase 
(ROCK), which stimulate LIM kinase to phosphorylate ADF/cofilin (Edwards et al., 
1999; Bishop and Hall, 2000; Schmitz et al., 2000; Ridley, 2001). Phosphorylation 
inactivates ADF/cofilin prolonging the lifetime of newly formed actin filaments. 
Interestingly, activation of small GTPases stimulates not only the formation but also 
stabilization of new filaments. Finally, profilin, a nucleotide-exchange factor for actin, 
binds tightly to the actin-monomers, refilling the actin-monomer pool.  
 
 
2.4. The microtubule cytoskeleton 
Microtubules are dynamic structures that provide mechanical support for cell shape and 
act as tracks along which molecular motors move structures such as organelles, 
chromosomes or mitotic spindles around the cell. Moreover, microtubules remodeling is 
important in migrating cells, in order to establish and maintain cell polarity. Microtubules 
are hollow tubes composed of protofilaments of α- and β- tubulin dimers organized in a 
head-to-tail fashion. Tubulin polymerizes more quickly from the plus end, which is 
terminated by a β-subunit. The other, slow growing end, is terminated with an α-subunit 
and is called the minus end (Mitchison, 1993). In many cell types, the minus end of 
microtubules is embedded in a microtubule-organizing center (MTOC), whereas the plus 
end explores the cytoplasmic space. Microtubules have a dynamic behavior: individual 
microtubules alternate between periods of growth and shrinkage, a property called 
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dynamic instability (Mitchison and Kirschner, 1984; Desai and Mitchison, 1997). The 
transition from growth to shrinkage is called catastrophe, and the one from shrinkage to 
growth is called rescue. The energy to drive microtubule polymerization comes from 
GTP hydrolysis. Tubulin is a GTPase whose activity is stimulated by polymerization 
(Erickson and O'Brien, 1992). Evidence coming from the atomic structure of tubulin 
shows that the β-subunit pocket can bind GTP, but lacks residues crucial for hydrolysis. 
These residues are given by the α-subunit when it binds to the end of the microtubule, 
triggering GTP hydrolysis (Nogales et al., 1999). Microtubules at the growing end 
consist of sheets of protofilaments (Chretien et al., 1995; Arnal et al., 2000), whereas 
microtubules at the shrinking end are curled (Mandelkow et al., 1991; Arnal et al., 2000). 
Therefore, it seems that there is a structural transition associated with the switch between 
microtubule growing and shrinking. These structural changes are dependent on the GTP 
hydrolysis. In fact it was shown that GTP-tubulin form straight protofilaments that fit 
nicely into the wall of the microtubules, whereas in the GDP state the protofilaments are 
bent and they splay out from the microtubule lattice.  
 
2.4.1. Microtubule end-binding proteins 
GTP hydrolysis is known to occur very fast during microtubule polymerization and 
thermodynamic studies revealed that GDP-tubulin makes the microtubules very unstable. 
Some proteins were shown to modulate microtubule dynamics. These molecules are 
called microtubule-associated proteins or MAPs (Andersen, 2000). Two distinct classes 
of end-binding proteins have been described: the MCAKs (for mitotic centromere-
associated kinesins, also called Kin I kinesins) which bind microtubule ends and 
destabilize them; and the plus-end-binding or tracking proteins (+TIPs) (Schuyler and 
Pellman, 2001), which also bind to the growing end of the microtubules, but stabilize 
microtubule growth.  
MCAKs use energy from ATP in order to bind to the end of microtubules and they attach 
preferentially to the bend form of the tubulin dimer. MCAKs probably destabilize 
growing microtubules by inducing the formation of the curl, which then weakens the 
association of the terminal tubulin dimer, triggering its dissociation. 
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The prototype for +TIPs is CLIP-170 (Perez et al., 1999). CLIP-170 binds to the 
microtubule plus end during their elongation and probably dissociates as the microtubule 
closes into a tube. Since the discovery of CLIP-170, more plus-end-binding proteins have 
been identified (Sawin, 2000; Schuyler and Pellman, 2001). For example the CLASP 
(CLIP associated proteins) proteins target microtubule end by binding to CLIP-170 and 
CLIP-115 (Akhmanova et al., 2001). EB1 is also binding to tips of growing 
microtubules, where it stabilizes the polymer during mitosis preventing catastrophes 
(Tirnauer and Bierer, 2000). The adenomatous polyposis coli protein (APC) also 
accumulates at growing microtubule plus ends, specifically in protruding areas of the 
cells (Nathke et al., 1996; Mimori-Kiyosue et al., 2000).  +TIPs have at least three 
different functions. First, they play a role in the regulation of microtubule dynamic 
behavior, modifying the probability of microtubule elongation, shrinkage and pausing 
(Brunner and Nurse, 2000; Komarova et al., 2002a; Komarova et al., 2002b). Second, 
+TIPs are involved in anchoring microtubules to cellular structures such as cortical actin 
which allow protein delivery at the cell periphery (Behrens and Nurse, 2002; Fukata et 
al., 2002). Third, it was shown that +TIPs regulate dynein motor protein activity, which 
plays a role in the organization of the cytoskeletal architecture (Valetti et al., 1999; 
Vaughan et al., 1999). 
 
2.4.2 Molecular motors 
 Molecular motors trigger most forms of movement in the cells. These motors transport a 
variety of cargos, power cell locomotion, drive cell division and when combined in large 
ensemble allow organisms to move. There are three classes of cytoplasmic motors: 
myosins, dyneins and kinesins. These proteins have a globular domain at one end, 
followed by a rod. The globular domain serves as a so-called “motor domain” that slides 
against the tracks using energy from ATP hydrolysis. The motor domains of kinesins and 
dyneins have ATP-binding and microtubule binding sites. They repeat cycles of 
attachment, sliding on the microtubules in an ATP-dependent manner, and move along 
the microtubules. Outside the motor domains, proteins from the same family can be quite 
different. These variable domains are the binding sites for the molecules to be transported 
(cargos); the diversity enables the motor proteins to participate in a wide variety of 
 26
intracellular transport. There is evidence that these cytoplasmic motors are involved not 
only in transport of organelles and vesicles (Lafont et al., 1994; Kreitzer et al., 2000), but 
also of messenger RNA and macromolecular complexes (Schliwa and Woehlke, 2003). 
Molecular motors are very important in the segregation of the chromosomes and in the 
motility of the mitotic spindle and in the cell scission (Scholey et al., 2003). Moreover, 
there is increasing evidence that a growing number of diseases are linked to molecular 
motors (Hirokawa and Takemura, 2003; Schliwa and Woehlke, 2003).  
Microtubule-dependent motor proteins are used for long-distance transport, for example 
from near the nucleus to the plasma membrane, whereas actin-dependent motor proteins 
are used for short distances. Both microtubules and actin filaments have polarity, and 
each motor protein moves unidirectionally. Most of the members of the kinesin 
superfamily move to the plus end of microtubules, whereas members of the dynein 
superfamily move to the minus end. 
 
 
2.5. Microtubules, actin cytoskeleton and Rho GTPases interplay 
Migrating cells are polarized with the lamellipodia facing the direction of migration. 
Protruding activity at the leading edge and retrograde flow of integrins coupled to 
adhesion of the lamellipodia near the leading edge are thought to be the driving force for 
cell motility. As described above, these activities are dependent on directed actin filament 
assembly and on the microtubule cytoskeleton. Although some small, specialized cell 
types such as keratocytes and leukocytes do not required microtubules for motility 
(Zigmond et al., 1981; Euteneuer and Schliwa, 1984), microtubules are necessary for the 
persistent, polarized movement of larger cells such as fibroblasts or epithelial cells 
(Vasiliev, 1991). Depolymerization of microtubules stops cells migration and induces 
loss of cell polarity, so that ruffling activity normally restricted to the leading edge 
becomes reduced and redistributed to the entire cell (Vasiliev, 1991). Recent studies have 
shown that actin has a major influence on the organization of microtubules. There is 
evidence that microtubules are transported in the lamella of migrating cells and that this 
transport depends on actin (Waterman-Storer and Salmon, 1997).  Moreover, other 
studies showed that, in the lamella, microtubules are coupled to actin retrograde flow, 
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whereas in the cell body microtubules are coupled to the anterograde motion of actin 
(Gupton et al., 2002; Salmon et al., 2002). Microtubule association to actin movement 
results in a gradient of microtubule assembly states in the cell, with plus-end growth at 
the leading edge and minus-end shortening in the cell body, behind the lamella. Several 
hypotheses have been proposed to explain how cells use actin-microtubules interactions 
to generate movement. One hypothesis is that cell motility depends on the structural 
linkage of microtubules to actin retrograde flow, which creates and maintains a 
regulatory Rho GTPases signaling gradient that triggers migration (Wittmann and 
Waterman-Storer, 2001). Microtubule growth at the leading edge could induce Rac 
activity in the cell front to drive lamellipodia protrusion and focal complexes formation.  
Rac activation, in turn promotes further microtubule growth reinforcing the polarization 
of a migratory cell in the absence of extracellular signals (Wittmann et al., 2003). One 
candidate that can mediate Rac activation driven by microtubule growth in migrating 
cells is APC. APC localized at the microtubule plus end (Nathke et al., 1996) and binds 
Asef, which is a Rac-specific GEF that stimulate lamellipodia formation and cell 
migration (Kawasaki et al., 2003). Another candidate is IQGAP1, which binds Cdc42, 
Rac and actin, but also associates with growing microtubule plus end via CLIP-170 
(Fukata et al., 2002). Another hypothesis is that actin-microtubule interactions adjust 
toward the leading edge, which could then direct the delivery of signaling molecules or 
membrane components required for lamellipodia formation (Gundersen, 2002). It was 
shown that MTOC reorientation during cell migration is mediated by Cdc42 and the 
microtubule motor dynein (Etienne-Manneville and Hall, 2001; Palazzo et al., 2001). 
Microtubules are crosslinked to specific sites defined by Cdc42 in the actin cortex and 
dynein may pull the MTOC in front of the nucleus.  
Moreover, microtubules-actin interactions may mediate specific spatiotemporal 
regulation of focal contacts with the substrate to guide cell movement. In fact, it has been 
shown that during dynamic instability microtubules specifically target focal contacts and 
that the targeting frequency is inversely proportional to the focal contact lifetime 
(Kaverina et al., 1999; Krylyshkina et al., 2003). Further evidence illustrates that the 
microtubule motor kinesin may deliver putative factors that promote focal adhesion 
turnover (Krylyshkina et al., 2002). Furthermore, microtubule shortening could activate 
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Rho behind the lamellipodia to drive actomyosin contraction and to promote stabilization 
of a subpopulation of microtubules, protecting them from breakage and thus maintaining 
a polarized microtubule cytoskeleton (Ren et al., 1999). There are evidences that the Rho 
exchange factor GEF-H1 is regulated by an interaction with microtubules (Ren et al., 
1998; Krendel et al., 2002). GEF-H1 is inactivated by microtubules binding and 
microtubules depolymerization can activate Rho by increasing the amount of free, active 
GEF-H1. Microtubules could serve to sequester GEF-H1 in the vicinity of adhesion sites 
and thereby reduce Rho activity, promoting adhesion turnover (Krendel et al., 2002). 
Microtubules are probably guided to focal adhesions by structural links to adhesion-
associated actin filaments, but the identity of these crosslinking proteins is still unknown 
(Salmon et al., 2002; Krylyshkina et al., 2003).  
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Abstract 
 
The Neu/ErbB2 tyrosine kinase receptor has an important function in tumor cell motility, 
an essential characteristic of metastatic cells. In this study, we show that activation of a 
set of signaling molecules, including MAP kinase, phosphatidylinositol 3-kinase and Src, 
is required for Neu/ErbB2-dependent lamellipodia formation and for motility of breast 
carcinoma cells. Stimulation of these molecules, however, fails to induce efficient cell 
migration in the absence of Neu/ErbB2 Tyr1201 or Tyr1227 phosphorylation. We 
describe a novel mediator of ErbB2-driven cell motility (Memo) that interacts with a 
phospho-Tyr1227-containing peptide via the Shc adaptor protein. Upon Neu/ErbB2 
activation, Memo-defective cells form actin fibers and grow lamellipodia, but fail to 
extend microtubules toward the cell cortex. Our data suggest that Memo controls cell 
migration by relaying extracellular chemotactic signals to the microtubule cytoskeleton.  
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The Neu/ErbB2 receptor tyrosine kinase is often overexpressed in human tumors of 
diverse origins including breast and ovaries1,2. Clinical studies have revealed that cancer 
patients whose tumors have alterations in ErbB2 expression tend to have more 
aggressive, metastatic disease, which is associated with parameters predicting a poor 
outcome3. In accordance with the clinical data, transgenic mice expressing activated Neu 
under the control of the mouse mammary tumor virus long terminal repeat develop 
metastatic mammary tumors4-6. Data from in vitro studies provide evidence that 
Neu/ErbB2 plays an important role in cancer cell motility and extracellular matrix 
invasion7-10. The molecular basis underlying ErbB2-dependent cell motility and 
metastases formation, however, still remains poorly understood.  
Activation of ErbB2 via dimerization with other ligand-bound ErbB members 
results in phosphorylation of tyrosine residues in the cytoplasmic tail11,12. These 
phosphotyrosines serve as high affinity binding sites for molecules containing Src 
homology 2 (SH2) or phosphotyrosine binding (PTB) domains such as the Shc and Grb2 
adaptor molecules13,14 or the p85 subunit of phosphatidylinositol 3-kinase (PI3K)15. 
These docking proteins transduce proliferative, transforming or migratory signals to the 
cell nucleus via activation of, for example, the Ras/mitogen-activated protein kinase 
(MAPK) and the PI3K pathways16-19, both of which regulate different processes 
associated with cell migration, including formation of lamellipodia and actin stress 
fibers20,21. There is also evidence that p38 kinase and c-Src induce actin reorganization 
via phosphorylation of focal adhesion proteins22,23. The precise contribution of each 
pathway to ErbB receptor-regulated cell migration, however, remains to be determined. 
The purpose of our study was to investigate the role of individual ErbB2 
autophosphorylation sites in migration of human breast carcinoma cells. Our results show 
that Neu/ErbB2 lacking the five major autophosphorylation sites is impaired in 
stimulating migration and that two of the sites, Tyr1201 and Tyr1227, are fully able to 
restore the migratory phenotype of breast carcinoma cells. Moreover, we demonstrate 
that Memo, a newly identified protein which interacts with phosphorylated Tyr1227, 
mediates ErbB2-driven cell migration by controlling microtubule outgrowth. 
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Results 
Role of specific ErbB2 tyrosine residues in heregulin-induced migration. 
 
It has previously been shown that the T47D breast carcinoma cell line, which expresses 
moderate levels of the four ErbB receptors, is dependent upon ErbB2 activity for 
migration in response to EGF-related ligands8. We have now investigated the role of 
individual ErbB2 autophosphorylation sites in migration. For that purpose, ErbB2 was 
first functionally inactivated in T47D cells by expressing a single chain antibody (scFv-
5R) that traps human ErbB2 in the endoplasmic reticulum24, thus inhibiting its transfer to 
the plasma membrane, as confirmed by the absence of ErbB2 surface staining (data not 
shown, Appendix Figure 1), and preventing ligand-induced ErbB2 activation25. Migration 
of parental and scFv-5R-expressing cells (T47D-5R) in response to heregulin β1 (HRG) 
was measured in Boyden-like chambers. HRG binding to ErbB3 and ErbB4 leads to the 
formation of active ErbB2-containing heterodimers. HRG strongly stimulated migration 
of T47D cells, while T47D-5R cells were unable to migrate beyond basal levels (Fig. 1a), 
confirming the essential role of ErbB2 in EGF-related peptide induced migration8. 
T47D-5R cells were transfected with expression vectors encoding either wild type 
Neu, the rat homologue of ErbB2, or mutant Neu with a Phe residue substituted in each 
of the five autophosphorylation sites (termed NYPD for Neu tyrosine phosphorylation 
deficient) or Neu add-back mutants harboring only one of the five autophosphorylation 
sites, called YA, YB, YC, YD and YE, corresponding to Tyr1028, Tyr1144, Tyr1201, 
Tyr1227 and Tyr1253, respectively (nomenclature according to Dankort et al.13) (Fig. 
1b). Cells expressing similar levels of wild type or mutant Neu were selected (data not 
shown, Appendix Figure 2) and their migration in response to HRG was evaluated. Neu 
efficiently replaced ErbB2 in T47D-5R cells, as demonstrated by their restored migratory 
response to HRG (Fig. 1c). In contrast, NYPD-, YA-, YB- and YE- expressing cells 
showed strongly reduced migration in response to HRG. It should be noted that each Neu 
mutant, despite lacking autophosphorylation sites, can interact with and 
transphosphorylate the other HRG- bound ErbB receptors, which likely explains the 
ability of these cells to migrate in response to HRG beyond the basal levels observed in 
the T47D-5R cells (Fig. 1a).  
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Intriguingly, migration of YC- and YD-expressing cells was equivalent to that of 
Neu-expressing cells (Fig. 1c), indicating that these two tyrosine residues couple to 
signaling pathways required for efficient cell migration. To verify their proposed role, 
tyrosine phosphorylated or non-phosphorylated peptides, corresponding to the region of 
Neu including the YC or YD residues, were used to compete for binding of signaling 
molecules to Neu. Peptide-mediated delivery26 of a phospho-YC peptide into YC-
expressing cells prevented HRG-induced migration (Fig. 2a), while the non-
phosphorylated peptide did not interfere significantly with migration. Similarly, only the 
phospho-YD peptide efficiently inhibited migration of YD-expressing cells (Fig. 2b). 
Moreover, the phospho-YD peptide did not inhibit migration of YC-expressing cells (Fig. 
2c) and conversely phospho-YC peptide did not interfere with migration of YD-
expressing cells (Fig. 2d). These results not only confirm the requirement for 
phosphorylation of YC or YD tyrosine residues for cell migration, but also show that 
these two tyrosines recruit distinct signaling complexes.   
 
HRG induces morphogenetic changes in T47D and NYPD cells  
 
Cell motility can be viewed as a series of morphogenetic events based on remodeling of 
the actin cytoskeleton. Thus, we analyzed HRG-induced changes in cell morphology and 
cytoskeleton organization in migratory and non-migratory cells. HRG-treated T47D cells 
rapidly spread and formed membrane ruffles. Initially, cells extended lamellipodia in all 
directions, before showing a more polarized organization, paralleling the formation of 
actin stress fibers (Fig. 3a, upper panel). Surprisingly, NYPD cells, while greatly 
impaired in migration (Fig. 1c), displayed a normal morphogenetic response, extending 
and organizing lamellipodia after HRG treatment (Fig. 3a, lower panel). Lamellipodia 
formation is dependent on the activation of Rac, a member of the Rho GTPase family27.  
The kinetics of HRG-induced Rac activation was similar in T47D and NYPD cells: in 
both cell lines activity was transient, peaking 5 min after HRG addition (Fig.3b). These 
results are in accordance with the morphological results and provide further evidence that 
T47D and NYPD cells undergo comparable cytoskeletal rearrangements shortly after 
HRG treatment.  
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Cytoskeleton remodeling is widely used as a read-out for cell motility. The fact 
that HRG-triggered actin reorganization in T47D and NYPD cells was essentially 
identical, was in apparent contradiction with HRG’s differential effect on migration of 
these cell lines. To minimize variations due to assay conditions, we analyzed lamellipodia 
formation in the same dual-chamber setting used to measure cell migration. T47D cells 
show a rapid increase in lamellipodia, apparent within an hour of HRG treatment, 
followed by a plateau and a second slower increase after 6 hrs (Fig. 3c & d). 
Interestingly, lamellipodia formation during the early time points (up to 4 hrs) was 
similar in Neu cells and in NYPD cells, but was strikingly altered at later times (Fig. 3d). 
These results confirm that early morphological and molecular changes, occurring in 
response to HRG are similar in migratory and non-migratory cells. Furthermore, they 
suggest that migration of NYPD cells is affected at a stage independent of lamellipodia 
formation.   
 
Signaling pathways involved in ErbB2-dependent migration. 
 
Our data show that the phosphorylated YC and YD residues of Neu/ErbB2 are crucial 
mediators of efficient, HRG-induced cell migration. Pathways implicated directly, or 
indirectly, in ErbB2-induced cytoskeleton remodeling and/or cell motility have 
previously been identified. These include the Ras/MAPK, PI3K, p38MAPK and Src 
kinase-dependent pathways20-23. Using selective kinase inhibitors on Neu cells, we 
determined that blocking each of these pathways led to a strong inhibition of HRG-
induced migration (Fig. 4a). While each of these pathways is required for migration, it is, 
however, not sufficient. Indeed, stimulation of the MAPK, PI3K, p38MAPK (Fig. 4b) 
and Src (data not shown, Appendix Figure 3) pathways did not correlate with migration, 
since HRG activated each pathway as efficiently in, e.g., NYPD or YA cells, as in Neu 
cells (Fig. 4b). As mentioned previously, Neu mutants can transphosphorylate the other 
ErbB receptors (ErbB3 or ErbB4), which likely explain activation of the examined 
pathways.  
Interestingly, the kinase inhibitors also had a negative effect upon the low level of 
HRG-induced migration observed for NYPD cells, with blockade of the MAPK and PI3K 
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pathways having the strongest effect (Fig. 4c). Moreover, both inhibitors also prevented 
Neu and NYPD cells from forming lamellipodia in response to HRG (Fig. 4d). The 
severe loss of polarity of lamellipodia induced by inhibitors of these two pathways is 
likely to contribute to the loss of chemotaxis. Thus, activation of the MAPK and PI3K 
pathways is essential for early stages of migration, involving remodeling of the actin 
cytoskeleton. In contrast, we propose that phospho-YC or -YD provide links to novel 
signaling pathway(s) controlling stages of cell migration not directly connected to 
lamellipodia formation.  
 
Identification of signaling molecules binding to the YC and YD residues 
 
To search for novel proteins that might link phospho-YC and -YD to signaling pathways 
mediating ErbB2-dependent migration, tyrosine-phosphorylated peptides, corresponding 
to the regions of Neu including the YC or YD residues, were coupled to agarose beads 
and employed as affinity reagents. The corresponding non-phosphorylated peptides 
served as controls. We performed a large-scale systematic identification of proteins from 
T47D cell extracts that bound specifically to the phospho-, but not to the non-
phosphorylated peptides, by high-pressure liquid chromatography-tandem mass 
spectrometry (LC-MSMS).  
A number of proteins were identified, some of which have been reported to bind 
ErbB2/Neu, others being novel interactors. Previous studies have shown that the adaptor 
molecules Shc and Crk II associated with the phospho-YD and -YC residues, 
respectively4,13. We also identified these two proteins in the LC-MSMS screen, finding in 
addition that Shc bound both phosphorylated peptides. Furthermore, not only CrkII, but 
also the CrkI splice variant and the Crk-like protein bound the phospho-YC peptide. 
Phospholipase Cγ (PLCγ), which has not previously been reported to interact with either 
of these tyrosine residues, was found to associate with the phospho-YC peptide. Finally, 
an uncharacterized protein, CGI-27 or c21orf19-like protein, that we have named Memo 
(see below), associated specifically with the phospho-YD peptide. The binding specificity 
of each protein was confirmed in independent experiments using the phospho- and non-
phosphorylated peptides as affinity reagents, followed by Western analysis (Fig. 5a). We 
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next investigated the in vivo interaction of Memo with ErbB2. Due to its high levels of 
expression, ErbB2 is constitutively activated in SKBr3 cells (Fig. 5b, P-ErbB2). In co-
immunoprecipitation experiments, Memo associated with ErbB2 only when the latter was 
activated and not in cells treated with the ErbB2 kinase inhibitor PKI16628 (Fig. 5b). We 
investigated the localization of ectopically-expressed Memo in SKBr3 cells. Memo was 
present at the plasma membrane of control SKBr3 cells (Fig.5c, upper panel). PKI166-
mediated inhibition of ErbB2 activity led to decreased membrane staining, while upon 
addition of HRG, Memo was concentrated in specific ruffle-like areas of the plasma 
membrane (Fig.5c, upper panel). While immunolocalization using the Memo anti-serum 
was less sensitive and did not reveal membrane-bound Memo in control SKBr3 cells, it 
still showed recruitment of Memo to the plasma membrane upon addition of HRG 
(Fig.5c, lower panel).  
The sequence of Memo does not contain SH2 or PTB phosphotyrosine-binding domains, 
known to interact with phosphotyrosines. The fact that Shc also interacted with the 
phospho-YD site raised the possibility that Shc, which has both a PTB and an SH2 
domain, mediates the binding of Memo to phospho-YD. In immunoprecipitation 
experiments, ectopically expressed Memo was found to interact with Shc in SKBr3 cells 
(Fig. 5d). Moreover, both endogenous Memo and ErbB2 co-immunoprecipitated with 
Shc in T47D cells (Fig. 5e). Immunodepletion of endogenous Shc from reticulocyte 
lysates did not significantly affect the levels of in vitro transcribed Memo, present in 
large excess, yet binding of Memo to the phospho-YD peptide was strongly decreased 
(Fig. 5f). These results strongly suggest that the Shc adaptor protein is a mediator of 
Memo binding to the phospho-YD residue.   
 
Role of phosphoYC/phosphoYD-binding proteins in cell migration. 
 
The identified proteins were next tested for their role in ErbB2-dependent cell migration. 
The function of Shc and Crk in HRG-induced migration was tested using small 
interfering (si) RNAs to block their expression. Specific siRNA transfection of YC or YD 
cells led to a strong decrease in the level of Shc (and Crk, data not shown, Appendix 
Figure 4) relative to mock-transfected cells (Fig. 6a, inserts). In contrast to control cells, 
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migration of YC and YD cells with reduced expression of Shc (Fig. 6a) or Crk or 
decreased PLC activity (not shown, Appendix Figure 4) was strongly inhibited. 
Furthermore, siRNA-mediated knock-down of Shc and Crk levels or inhibition of PLC 
activity prevented Neu and NYPD cells from forming lamellipodia in response to HRG 
(Fig. 6b).  Taken together, the results show that Shc, Crk and active PLCγ are required 
for HRG-induced cell migration. However, in contrast to the proteins we are seeking, 
they are involved in lamellipodia formation.  
 
Memo, a mediator of ErbB2-driven cell motility 
 
The function of Memo, the novel protein identified as a specific phospho-YD binder, is 
unknown. Furthermore, its sequence does not provide any information on a potential role 
in migration. Thus, we tested Memo’s function using specific siRNA to knock-down its 
expression.  Quantitative PCR revealed that Memo mRNA expression was  ~ 80% lower 
in Memo siRNA transfected cells relative to cells treated with a control siRNA (Fig. 6c, 
insert). We have verified that the decrease in Memo RNA was paralleled by a decrease in 
Memo protein expression (data not shown, Appendix Figure 5). Importantly, loss of 
Memo strongly decreased migration of YD cells in response to HRG (Fig. 6c). Based 
upon these and the following results, it was named Memo for mediator of ErbB2-driven 
cell motility. 
Inhibition of Memo’s expression had a strong effect on HRG-induced migration 
of YD, but not YC cells, demonstrating that Memo acts specifically downstream of the 
YD tyrosine residue (Fig. 6e). In addition, Memo siRNA did not affect NYPD-expressing 
cells (Fig. 6e), whose migration is dependent on e.g. the MAPK and the PI3K pathways 
(Fig. 4). Importantly, HRG-induced formation of lamellipodia was not affected by a 
reduction in Memo levels (Fig. 6d), showing that, in contrast to the other identified 
signaling molecules, Memo is not involved in this step of cell migration. Based upon 
these results, we propose that Memo is a signaling molecule that links phosphorylated 
YD to stages of cell migration, independent of early cytoskeletal actin reorganization. 
Our data demonstrate that Memo is required for migration of YD cells. HRG-
induced migration of Neu-expressing cells (Fig. 6e) and parental ErbB2-expressing T47D 
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cells (Fig. 7a) was also dependent (by at least 50%) on Memo’s expression. Thus, in the 
context of the wild type receptor, YC-dependent signaling is not able to fully offset the 
loss of functional Memo.  
 The SKBr3 and MDA-MB-231 cell lines are frequently used as experimental 
breast tumor models. Constitutive activation of ErbB2 in SKBr3 cells promotes 
constitutive signaling of the MAPK and PI3K pathways29,30. Despite this, SKBr3 cells 
display only low migration in the absence of ligands. In contrast, MDA-MB-231 cells 
show high basal motility in the absence of ligands and display metastatic growth in 
animal models. SKBr3 and MDA-MB-231 cells with reduced Memo levels showed 
decreased HRG-induced migration (Fig. 7a). Moreover, reduction in Memo’s expression 
also lowered basal migration of MDA-MB-231 cells (Fig. 7a), which likely reflects the 
presence of autocrine activated ErbB2 in these cells (data not shown, Appendix Figure 6).  
Finally, we examined the role of Memo downstream of other tyrosine kinase 
receptors. Fibroblast growth factor (FGF) 2 and, to a lower degree, insulin and epidermal 
growth factor (EGF) stimulated T47D cell migration (Fig. 7b). SiRNA-mediated knock-
down of Memo did not affect insulin-dependent migration, but strongly reduced FGF2- 
and EGF-induced cell migration (Fig. 7b), indicative of a more widespread role for 
Memo in receptor tyrosine kinase-induced cell motility.  
 
Memo is required for ErbB2-dependent microtubule outgrowth 
 
Recent studies demonstrate the central role of the microtubule cytoskeleton for 
cell polarity and cell migration31. HRG induces the extension of microtubules from the 
centrosome to the cell periphery in T47D and SKBr3 cells (data not shown, Appendix 
Figure 7). However, when Memo’s expression was inhibited, the network of 
microtubules induced by HRG was strongly reduced (Fig. 8a). The number of T47D and 
SKBr3 cells showing showing microtubule outgrowth is reduced from around 80% in 
control cells to 20% in cells transfected with Memo siRNA (Fig. 8b). Furthermore, actin 
stress fibers appeared to be increased when microtubule outgrowth was prevented. 
Interestingly, the central microtubule network, which is present regardless of ErbB2 
activation, was not affected by the decrease in Memo’s expression. This data show that 
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Memo is required for the ErbB2-dependent elongation of microtubules toward the cell 
cortex.  
 
 
Discussion   
  
The results presented here demonstrate that Neu/ErbB2-induced cell migration depends 
on the cooperative action of many signaling molecules working in concert to regulate 
discrete steps of the process.  Ras/MAPK, PI3K, p38MAPK and Src-mediated signaling 
were all found to be indispensable for HRG-induced lamellipodia outgrowth and motility. 
In the absence of signaling pathway lying directly downstream of Tyr1201 and Tyr1227, 
however, their activation leads to only modest cell migration.  
In this respect, we have identified a new mediator of Neu/ErbB2 signaling, 
Memo, which interacts specifically with phospho-Tyr1227 and is required for breast 
carcinoma cell migration. Memo corresponds to the CGI-27/c21orf19-like hypothetical 
protein, which was identified by comparative gene identification using the C. elegans 
proteome as a template32, but was not attributed a function yet. It is conserved throughout 
evolution: proteins homologous to Memo exist in yeast, nematodes, drosophila and 
mammals. Its sequence shows no domain of identified function and does not provide 
information on how it might associate with phospho-Tyr1227. In fact, our results indicate 
that Memo binds to the phospho-Tyr1227 peptide via the Shc adaptor protein. 
Intriguingly, Memo does not bind to the phospho-Tyr1201 peptide, even though Shc 
does. This might be explained by the fact that Shc can associate with phosphorylated 
tyrosines using either the SH2 or the PTB domain19,33,34 and thus, could adopt different 
conformations allowing the recruitment of different signaling molecules. Whether 
binding of Memo to Shc depends on the domain by which Shc interacts with the 
phosphotyrosine remains to be determined. 
Unlike other investigated signaling molecules, Memo is not involved in stages of 
cell migration, such as lamellipodia formation, which are linked to remodeling of the 
actin cytoskeleton. We found that Memo is required for the extension of a microtubule 
network to the cell periphery. Microtubules grow out from the centrosome, their plus 
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ends exploring the cytoplasm through alternate phases of growth and shortening, a 
phenomenon termed dynamic instability. Microtubule dynamics can be modulated by two 
types of molecules; microtubule-associated proteins such as MCAK (mitotic centromere-
associated kinesins), which bind to microtubule ends and destabilize them; and plus-end 
binding proteins, which favor microtubule growth through binding to the growing end, 
allowing microtubules to reach their target destination35. HRG triggers the growth of 
microtubules from the centrosome to the cell cortex. This does not occur in the absence 
of Memo. Thus, Memo could be a linker between extracellular chemotactic cues and the 
microtubule cytoskeleton, allowing the stabilization of outgrowing microtubules and the 
maintenance of cell polarity. Whether Memo prevents microtubule destabilization or 
promotes microtubule extension is still under investigation. Wittman et al.36 recently 
described a population of central microtubules with little or no net growth. We also 
observed a population of stable central microtubules in both resting and ligand-activated 
cells. Interestingly, Memo is not required for the organization or maintenance of the 
central microtubules, indicating a specific role for Memo in stabilizing the most dynamic 
microtubules, extending toward the protruding membrane of migrating cells. 
Microtubules are also a key element for cell division. The fact that Memo is not required 
for microtubule organization in general, but specifically for microtubule outgrowth 
within lamellipodia, can explain why knocking down Memo’s expression does not 
interfere with breast carcinoma cell proliferation (RM and AB, unpublished observations, 
Appendix Figure 8).  
Both T47D and SKBr3 cells are capable of extending polarized lamellipodia in 
the absence of microtubule outgrowth. Similarly, nocodazole-treated cells do not grow 
microtubules, but are still capable of forming lamellipodia (RM and AB, unpublished 
observations, Appendix Figure 9) indicating that microtubule outgrowth is not required 
for early actin cytoskeleton remodeling. However, we have observed that in cells lacking 
Memo, while microtubule outgrowth is inhibited, the amount of actin stress fibers 
appears to be increased. It was previously shown that depolymerization of microtubules 
triggers the formation of stress fibers37. The Rho GTPase-exchange factor GEF-H1 was 
recently identified as a stress-fiber-inducing factor38; GEF-H1 stimulates Rho activity and 
stress fiber formation, only when it is not bound to microtubules. While the factors 
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leading to increased stress fibers when Memo is knocked down are not known, our 
observations highlight the dynamic interactions that take place between the actin and the 
microtubule cytoskeleton in migrating cells. Ongoing studies are aimed at understanding 
the role of Memo in the targeting of microtubules to cell cortical regions and how this 
contributes to cell polarization and directed cell motility. 
 
 
Methods 
 
Plasmid constructs, cell culture, cell transfection  
T47D, SKBr3 and MDA-MB-231 breast carcinoma cells were cultured in Dulbecco’s 
modified Eagle’s medium supplemented with 10% fetal calf serum (GIBCO Invitrogen 
AG, Basel, Switzerland). T47D-5R cells were obtained by infection of T47D cells with a 
pBabe-based retrovirus expressing the scFv-5R cDNA, as previously described24. The 
infected cells were selected in 1 mg/ml G418 (GIBCO) and clones were generated and 
tested for the absence of surface ErbB2 by FACS. Cells were then transfected with 
plasmids encoding Neu or Neu phosphorylation mutants13 with a wild-type 
transmembrane sequence (V664) using FuGene (Roche Diagnostics Corporation, 
Indianapolis, IN, USA) and selected in 1 µg/ml puromycin (Sigma, St. Louis, MI, USA). 
In order to obtain cells expressing similar amounts of Neu receptor, cells were sorted 
after surface staining with a Neu specific antibody (Oncogene, Darmstadt, Germany). 
Memo cDNA, obtained by RT-PCR using RNA of T47D cells as a template, was first 
cloned into pGEM-T Easy (Promega Corporation, Madison, WI, USA), then subcloned 
into pcDNA3-derivatives containing the Myc epitope to generate the N-terminally tagged 
fusion proteins Myc-Memo. Constructs were verified by sequence analysis and 
transfected into SKBr3 cells using FuGene. 
 
Migration assay 
Cell migration was tested using 8 µm-pore polycarbonate membrane Transwell chambers 
(Corning Costar Products, Acton, MA, USA) as described previously39. In brief, the 
bottom side of the membrane was coated with 25 µg/ml rat tail collagen I (Roche). Serum 
starved cells were plated in the top Transwell chamber. Medium with or without 1 nM 
HRG-β1 (R&D systems, Inc., Minneapolis, MN, USA) was added to the bottom chamber 
and cells were allowed to migrate for 24 hours. Non-migrated cells were scraped off the 
top of the membrane. Migrated cells were fixed in 4% formaldehyde and stained in 0.1% 
crystal violet. Cells were counted under a microscope in ten high power fields. Migration 
was expressed as cell number per mm2. In some instances, cells were pre-incubated for 
60 minutes with the UO126 MEK inhibitor (50 µM; Promega), the LY294002 PI3K 
inhibitor (50 µM; Calbiochem-Novabiochem Corporation, San Diego, CA, USA), the 
SB203580 p38 MAPK inhibitor (20 µM; Calbiochem), the CGP77675 Src inhibitor (2.5 
µM; kindly provided by M. Šuša and J. Green, Novartis, Basel, Switzerland) or the U-
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73122 PLC inhibitor (2 µM; Calbiochem). Cells were then allowed to migrate for 8 hours 
before counting. 
 
Immunoprecipitation and western blot 
Cells were lysed in NP-40 lysis buffer (50 mM Hepes pH 7.4, 150 mM NaCl, 25 mM β-
glycerol phosphate, 25 mM NaF, 5 mM EGTA, 1 mM EDTA, 1% NP-40, 10 µg/ml 
leupeptin, 10 µg/ml aprotinin, 10 µg/ml sodium vanadate and 100 µM 
phenylmethylsulfonyl fluoride) for 5 minutes on ice. For immunoprecipitation, equal 
amount of proteins were incubated for 1 hour with a Shc antibody from BD Transduction 
laboratories (Heidelberg, Germany) or an ErbB2-specific 21N polyclonal antiserum40. 
Immunocomplexes were collected with protein A-Sepharose (Sigma) and washed three 
times with lysis buffer and proteins were released by boiling in sample buffer. Proteins 
were blotted on polyvinylidene difluoride membranes (Millipore GmbH, Vienna, 
Austria) and probed with specific antibodies: P-p44/42, P-Akt/PKB and  P-p38MAPK 
from New England Biolabs (Beverly, MA, USA), Myc from Santa Cruz Biotechnology, 
Inc. (Santa Cruz, CA, USA), Shc, 21N antiserum, phosphotyrosine-specific mAb25 and 
affinity purified polyclonal antiserum directed against Memo (amino-acids 61 to 75). 
Proteins were visualized with peroxidase-coupled secondary antibodies using the 
enhanced chemiluminescence detection system (Amersham Pharmacia Biotech, 
Dübendorf, Germany). 
 
Rac activity assay 
Active Rac was detected using a glutathione-S-transferase (GST)-PAK- CRIB domain 
(CD) fusion protein (kindly provided by J. G. Collard, the Netherlands Cancer Institute, 
Amsterdam) as described previously41. Briefly, lysates from cells plated on collagen-
coated dishes were incubated with bacterially produced GST-PAK-CD fusion protein 
bound to glutathione-coupled Sepharose beads. Proteins bound to the fusion protein were 
analyzed by Western blotting using an anti-Rac1 antibody (Upstate biotechnology, Lake 
Placid, NY, USA). Aliquots from the cell lysates were taken in order to analyze total 
amount of Rac1. 
 
Immunofluorescence and actin staining  
Cells were grown on glass coverslips (Falcon, Le Pont De Claix, France) coated with 25 
µg/ml rat tail collagen I, serum starved overnight and stimulated with 1 nM HRG-β1 for 
different times. In some experiments the cells were pre-incubated for 60 minutes with the 
ErbB2 inhibitor, PKI166 (5 µM, kindly provided by P. Traxler, Novartis28). Cells were 
fixed in 4% formaldehyde in phosphate buffer saline (PBS) for 20 minutes, 
permeabilized in 0.2% Triton X-100 for 10 minutes, blocked with 1% bovine serum 
albumin in PBS for 20 minutes before addition of anti-Myc, anti-Memo or anti-α-tubulin 
antibody (kindly provided by W. Krek, ETH, Zürich) and the appropriate fluorophore-
labeled secondary antibody (Molecular Probes, Leiden, The Netherlands). DNA was 
counterstained with 0.25 mg/ml Hoechst No. 33342 (Sigma). Actin was stained for 45 
minutes with 2U/ml TRITC-labeled phalloidin (Sigma) or Alexa-Fluor 488 phalloidin 
(Molecular Probes). Images were recorded with an Axioskop Zeiss microscope coupled 
to a Sony 3CCD camera or an Olympus IX70 microscope linked to the DeltaVision 
workstation (Applied Precision, Issaquah, WA). 
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Purification of lamellipodia 
Proteins localized in lamellipodia were specifically purified using the method described 
by Cho et al.42. Briefly, cells were plated on 3 µm porous polycarbonate membrane 
Transwell chamber (Costar) coated on the bottom side with rat tail collagen I. The lower 
chamber contained medium with or without 1 nM HRG-β1. Cells were allowed to extend 
lamellipodia through the pores for different times. Cell bodies remaining on the upper 
surface were removed and the lamellipodia extending to the lower surface were recovered 
in lysis buffer. Protein concentration was measured using Bio-Rad Dc protein assay (Bio-
Rad Laboratories, Hercules, CA, USA).  
 
SiRNA and peptide transfection  
Cells were transfected with siRNA using Oligofectamine (GIBCO) according to the 
manufacturer’s instructions. The following 21-mer oligoribonucleotide pairs (obtained 
from Xeragon Inc., Huntsville, AL, USA) were used: for Shc (accession number 
HSU7377) nucleotide 236 to 25643, for Memo (CGI-27; accession number AF132961) 
nucleotide 460 to 480 and for control LacZ (from D. Cappellen, FMI, Basel; accession 
number M55068) nucleotide 4277 to 4297. Cells were plated for migration assays 3 days 
after siRNA transfection and allowed to migrate for 24 hours. Cell lysates were also 
prepared 3 and 4 days after transfection and analyzed by Western blotting using a specific 
anti-Shc antibody. For Memo, RNA was extracted using RNeasy Mini (Qiagen, Cologne, 
Germany) and quantitative radioactive PCR44 was performed using Memo specific 
primers (forward from nucleotide 90 to 111 and reverse from nucleotide 256 to 235).  
Peptides were delivered into cells using the Chariot peptide carrier26 (Active 
Motif, Rixensart, Belgium) according to the instruction manual. 16 aa-peptides spanning 
tyrosine residue 1201 of Neu (YC peptide) and tyrosine residue 1227 of Neu (YD 
peptide) were obtained from Neosystem (Strasbourg, France) in phosphorylated and non 
phosphorylated forms. Cells were plated for migration 30 minutes after peptide 
transfection and the assay was finished after 22 hours. 
 
Pull-down assay and mass spectrometry 
Phosphorylated and non-phosphorylated YC and YD peptides were coupled under 
anhydrous conditions to Affi-gel 10 agarose beads (Bio-Rad). Coupled beads were 
incubated with 0.5 mg (for Western blotting) or 12 mg (for mass spectrometry) T47D cell 
lysates. Proteins bound to the peptides were subjected to SDS-PAGE. For mass 
spectrometry the gels were stained with Coomassie Brilliant Blue R-250. Each lane of the 
gels was sliced and analyzed by LC-MSMS (LCQ Deca XP, Thermo Finnigan) and 
proteins identified by Turbo Sequest. Proteins identified by more than two peptides and 
binding specifically to the phosphorylated form of the peptides were selected for further 
analysis. Binding was confirmed by Western blotting using antibodies against CrkII and 
PLCγ (Santa Cruz) , Shc and Memo. In some experiments, Shc was immunodepleted 
from reticulocyte lysates expressing in vitro translated Myc-Memo using the anti-Shc 
antibody, before performing the pull-down assay. 
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Figure legends 
 
Figure 1 Tyr1201 (YC) and Tyr1227 (YD) are required for HRG-induced cell 
migration. a, Parental T47D and T47D lacking functional ErbB2 (T47D-5R) were 
assayed for their ability to migrate in response to HRG. A typical experiment is shown; 
bars represent the average number of cells migrated per mm2, error bars represent s.d. b, 
Schematic representation of Neu, NYPD and the add-back mutants used in this study; 
YA, YB, YC, YD and YE correspond to Tyr1028, Tyr1144, Tyr1201, Tyr1227 and 
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Tyr1253 of Neu, respectively. c, T47D-5R cells expressing the different Neu constructs 
were tested for their ability to migrate in response to HRG. 
 
Figure 2 Effect of YC- or YD-containing synthetic phosphopeptides on HRG-
induced cell migration. a-d, YC- and YD-expressing cells were transfected with YC, 
phosphorylated YC (pYC), YD or phosphorylated YD (pYD) peptides as indicated and 
migration of YC- and YD-expressing cells in response to HRG was analyzed. 
 
Figure 3 Neu and NYPD cells both form lamellipodia upon HRG stimulation. a, 
T47D and NYPD cells were treated for different times with HRG, then F-actin was 
visualized with TRITC-labeled phalloidin. b, Rac activity in HRG-stimulated T47D and 
NYPD cells was measured via pull-down of GTP-bound Rac1 using beads coupled to a 
GST-PAK-CD fusion protein (upper panels). The total amount of Rac1 is shown in the 
lower panels. c, Lamellipodia formed in response to HRG were collected from T47D 
cells plated on a 3 µm porous membrane Transwell chamber and their concentration was 
measured and plotted with time. d, The concentration of lamellipodia from HRG-treated 
Neu and NYPD cells was determined as in c. The average of two independent 
experiments is shown. 
 
Figure 4 Activity of the MAPK, PI3K and p38MAPK pathways is required, but is 
not sufficient for Neu/ErbB2 dependent cell migration. a, HRG-induced migration of 
Neu cells was tested in the presence of MEK, PI3K, p38 or Src inhibitors. b, Activation 
of the MAPK, PI3K and p38MAPK pathways in response to HRG was assayed in the 
NYPD- and add back mutant-expressing cells. Cell extracts were analyzed by Western 
blotting and membranes were probed with P-MAPK, P-PKB and P-p38 antibodies. c, 
HRG-dependent migration of NYPD cells was tested in the presence of MEK, PI3K, p38 
or Src inhibitors. d, Effect of MEK and PI3K inhibitors on HRG-induced lamellipodia 
formation in Neu and NYPD cells 
 
Figure 5 Memo interacts with ErbB2 Tyr1227 via the Shc adaptor molecule . a, 
Binding of Shc, CrkII, PLCγ and Memo to YC, pYC, YD and pYD peptides was 
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analyzed by peptide pull-down, followed by Western blotting with the respective 
antibodies. Whole cell extracts (W) were also loaded on the gel. b, Myc-Memo-
expressing SKBr3 cells were pretreated or not with the ErbB2 inhibitor PKI166. Cell 
lysates were immunoprecipitated with ErbB2, analyzed by Western blotting and the 
membrane probed with antibodies against Myc, phosphotyrosine or ErbB2. c, Memo 
cellular localization in Myc-Memo-expressing and untransfected cells was visualized 
using respectively an antibodies against Myc (upper panel) or Memo (lower panel) in 
control, PKI166- or HRG-treated SKBr3 cells. Arrows indicate the cell membrane. d,  
Myc-Memo-expressing SKBr3 cells were pretreated or not with PKI166, before Shc 
immunoprecipitation and probing with anti-Myc and anti-Shc antibodies. e, T47D cells 
were stimulated or not with HRG and cell extracts analyzed by immunoprecipitation of 
Shc and probing for ErbB2, Memo and Shc. f, Shc was immunodepleted from 
reticulocyte lysates expressing in vitro translated Myc-Memo and Myc-Memo interaction 
with the pYD peptide was tested in control and Shc-depleted lysates.  
 
Figure 6 Memo is required for ErbB2-driven cell motility, but not for lamellipodia 
formation. a, HRG-dependent migration of YC and YD cells was tested after Shc siRNA 
transfection. Protein extracts were collected 3 and 4 days (3d and 4d) after transfection. 
The effect of Shc siRNA on Shc expression was verified by Western blotting using a Shc 
specific antibody (insert). b, HRG-dependent lamellipodia outgrowth was visualized in 
Neu and NYPD cells in the presence of Shc or CrkII siRNA or a PLC inhibitor. c, HRG-
dependent migration of YD cells treated with control (LacZ) or Memo siRNA was 
analyzed. RNA was collected 3d and 4d after transfection and Memo mRNA was 
measured by quantitative PCR (insert). d, HRG-induced lamellipodia formation in YD 
cells was observed in the presence of control (LacZ) or Memo siRNA. e, Effect of Memo 
siRNA on HRG-induced migration of Neu, NYPD, YC and YD cells was measured.  
 
Figure 7 Memo is a mediator of growth factor-induced breast carcinoma cell 
motility. a, HRG-dependent migration of T47D, SKBr3 and MDA-MB-231 cells was 
tested after Memo siRNA transfection. b, Effect of Memo siRNA on migration of T47D 
cells in response to  HRG, FGF2, insulin and EGF. 
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 Figure 8 Memo is required for ErbB2-dependent microtubule outgrowth. a, The 
actin and the microtubule cytoskeleton were visualized in HRG-stimulated T47D cells 
treated with control or Memo siRNA using Alexa-Fluor 488-phalloidin and an anti-α-
tubulin antibody, respectively. Arrows indicate the cell membrane. b, Microtubule 
outgrowth was evaluated in cells treated with HRG for 30 min, in the presence of control 
or Memo siRNA. For T47D cells n=321 and 347 for LacZ and Memo siRNA respectively 
and for SKBr3 cells n=348 and 256 for LacZ and Memo siRNA, respectively. 
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1.1. Appendix 
 
Figure 1. Surface staining of T47D and T47D-5R cells 
 
Background
T47D-5R
T47D cells
ErbB2
C
el
l n
um
be
r
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 84
Figure 2. Surface staining of wild type Neu or Neu add-back mutant expressing cells 
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Figure 3. Activation of Src in T47D and NYPD cells 
 
• Immunopreciptiation of the Src substrate cortactin followed by western blot for 
phosphotyrosine 
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Figure 4. Downregulation of CrkII and inactivation of PLC in YC cells: effects on 
cell migration 
 
• CrkII western blot of YC and YD cells transfected with mock or CrkII siRNA.  
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• Migration assay of YC and YD cells transfected with mock or CrkII siRNA. 
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• Migration assay of YC and YD cells treated with the U-73122 PLC inhibitor. 
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Figure 5. Memo protein levels 
 
Western blot of T47D cells transfected with LacZ or Memo siRNA with an antibody 
against Memo  
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Figure 6. Migration of MDA-MB-231 cells was tested with Memo siRNA and /or the 
ErbB2 kinase inhibitor PKI166 
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Treatment of the MDA-MB-231 cells with PKI166 lowers the HRG-induced 
migration, but also the basal cell migration, which is dependent on the autocrine 
activated ErbB2 in these cells. Interestingly, the combination of PKI166 with the 
downregulation of Memo does not have an addictive effect, suggesting that Memo 
acts downstream of ErbB2. 
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Figure 7. Microtubule staining of T47D cells, which were stimulated with HRG for 
different times, using an anti-tubulin antibody  
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Figure 8. Proliferation of T47D, SKBr3 and MDA-MB-231 cells transfected or not 
with Memo siRNA in the presence or absence of HRG 
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Figure 9. Effect of nocodazole on lamellipodia formation of T47D cells  
 
Nocodazole mediated disruption of the microtubule network has no effect on the ability 
of the cells to form lamellipodia. Interestingly, long-term nocodazole treatment also leads 
to the disruption of the central microtubules, but has no consequence on the actin 
cytoskeleton remodeling. 
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Additional materials and methods 
 
Surface staining 
Cells were trypsinized and washed in PBS prior to staining. Approximately 106 cells were 
then resuspended in 500 µl of PBS containing 5 µg/ml of the ErbB2 mAb FSP77 
(Appendix Figure 1) or 1 µg/ml of the Neu mAb (Appendix Figure 2). After incubation 
on ice for 1 hour, cells were washed three times in PBS. Bound antibodies were stained 
for 1 hour with fluorescent-labeled anti-mouse secondary antibody (from Amersham 
Pharmacia Biotech). Finally, the cells were washed three times in PBS, resuspended in 
500 µl of PBS, and analyzed for their fluorescence with a Becton Dickinson FACScan. 
 
SiRNA transfection 
Cells were transfected with siRNA using Oligofectamine (GIBCO) according to the 
manufacturer’s instructions. For CrkII (accession number NM_016823) the 21-mer 
oligoribonucleotide pair from nucleotide 454 to 474 was used. For Memo (accession 
number AF132961) the following 21-mer were used: Memo1 from nucleotide 460 to 480, 
Memo2 from nucleotide 232 to 252 and Memo3 from nucleotide 701 to 721. Cells were 
plated for migration assays 3 days after siRNA transfection and allowed to migrate for 24 
hours. Cell lysates were also prepared 3 and 4 days after transfection and analyzed by 
Western blotting using a specific anti-CrkII antibody (Santa Cruz). 
 
Proliferation assay 
T47D, SKBr3 and MBA-MD-231 cells were transfected with LacZ or Memo siRNA as 
described before. Cells were trypsinized 3 days after siRNA transfection and counted. 
Same numbers of cells (2*105 for T47D and SKBr3 cells and 105 for MDA-MB-231) 
were plated in triplicate in the presence or not of 1nM HRG-β1. Cells were allowed to 
proliferate for 3 days and then were trypsinized and counted in a hemocytometer. 
(Appendix Figure 8) 
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Immunofluorescence of T47D cells after nocodazole treatment 
Cells were grown on glass coverslips coated with 25 µg/ml rat tail collagen I, serum 
starved overnight and pre-incubated for 18 hours or 20 minutes with nocodazole at 
concentrations of 5nM or 5µM, respectively (Sigma). The cells were then stimulated with 
1 nM HRG-β1 for different times. Cells were fixed in 4% formaldehyde in PBS for 20 
minutes, permeabilized in 0.2% Triton X-100 for 10 minutes, blocked with 1% bovine 
serum albumin in PBS for 20 minutes before addition of the anti-α-tubulin antibody and 
the Alexa Fluor 594 goat anti-rat secondary antibody. DNA was counterstained with 0.25 
mg/ml Hoechst No. 33342 (Sigma). Actin was stained for 45 minutes with 2U/ml Alexa-
Fluor 488 phalloidin (Molecular Probes). Images were recorded with an Olympus IX70 
microscope linked to the DeltaVision workstation (Applied Precision, Issaquah, WA). 
(Appendix Figure 9) 
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1.2.  Information about Memo 
 
 
Memo= mediator of ErbB2-driven cell motility 
(CGI-27 or c21orf19 like proteins) 
 
 
 
1.2.1. Characterization of Memo  
 
• Memo was discovered by comparative genome identification: 
The C. elegans proteome was used as scaffold to assist in novel human 
gene identification from human EST nucleotide databases 32.  
 
• Memo encodes a predicted protein of 297 residues (molecular weight 
33.7kD). 
 
• The human gene maps to chromosome 2 [2p23.2]. There are also two 
pseudogenes, one on chromosome 6 and the other one on chromosome 21. 
 
 
 
 
 
 
• The Memo gene contains 9 exons. 
 
• Regarding the protein structure, Memo has no domain of identified 
function. 
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1.2.2. Memo in the evolution 
 
 
Memo is very well conserved during evolution, from yeast to mammals. 
 
 
 
Sequence identity: 
 
Human 100% 
Mouse 99% 
Zebrafish 88% 
Drosophila 65% 
C. elegans 53% 
S. Pombe 42% 
S. cerevisiae 40% 
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1.2.3. Memo sequence alignment (alignment done with T-coffee):  
 
Symbol code: * Identical   Color code: BAD AVG GOOD 
    : Highly similar 
   . Poorly similar 
 
Human      MSNRVV---CREASHAGSWYTASGPQLNAQLEGWLSQVQSTKRPARAIIAPHAGYTYCGS 
Mouse      MSNRVV---CREASHAGSWYTASGPQLNAQLEGWLSQVQSTKRPARAIIAPHAGYTYCGS 
Zebrafish  MSNRMV---CREASHAGSWYTASGSQLNAQLEGWLSQAQSIAGPARAIIAPHAGYTYCGA 
Drosophila ----MS---ARRATHAGSWYTDSGAELSRQLDRWLGAADLSHGPARAIIAPHAGYTYCGA 
C. elegans MSLNGFGEHTRSASHAGSWYNANQRDLDRQLTKWLDNA-GPRITARALISPHAGYSYCGE 
 
Cons            * *:******. .  :*. **  **. .     .***:*:*****:***  
 
 
Human      CAAHAYKQVDPSITRRIFILGPSHHVPLSRCALSSVDIYRTPLYDLRIDQKIYGELWKTG 
Mouse      CAAHAYKQVDPSVTRRIFILGPSHHVPLSRCALSSVDIYRTPLYDLRIDQKIYGELWKTG 
Zebrafish CAAHAYKQVDPSITRRVFILGPSHHVPLSRCALSPAEVYRTPLYDLRIDQKVYADLWKTG 
Drospohila CAAFAYRQVSPVVVKRIFILGPSHHVRLRGCALSVAKKYRTPLYDLKIDAQINSELEKTG 
C. elegans TAAYAFKQVVSSAVERVFILGPSHVVALNGCAITTCSKYRTPLGDLIVDHKINEELRATR 
 
Cons   **.*::** .  ..*:******* * *  **::  . ***** ** :* ::  :*  *  
 
 
Human      MFERMSLQTDEDEHSIEMHLPYTAKAMESHKDEFTIIPVLVGALSESKEQEFGKLFSKYL 
Mouse MFERMSLQTDEDEHSIEMHLPYTAKAMESHKDEFTIIPVLVGALSESKEQEFGKLFSKYL 
Zebrafish  MFERMSLQTDEDEHSIEMHLPYTAKAMENHKDEFSIVPVLVGALSGSKEQEYGKLLSKYL 
Drosophila KFSWMDMKTDEDEHSIEMHLPYIAKVMEDYKDQFTIVPILVGSLNPEQEAQYGSLLSSYL 
C. elegans HFDLMDRRDEESEHSIEMQLPFIAKVMGSKR--YTIVPVLVGSLPGSRQQTYGNIFAHYM 
 
Cons   *. *. : :*.******:**: **.* . :  ::*:*:***:*  .::  :*.::: *: 
 
 
Human     ADPSNLFVVSSDFCHWGQRFRYSYYDE-SQGEIYRSIEHLDKMGMSIIEQLDPVSFSNYL 
Mouse     ADPSNLFVVSSDFCHWGQRFRYSYYDE-SQGEIYRSIEHLDKMGMSIIEQLDPVSFSNYL 
Zebrafish  ADPSNLFIISPDFCHWGQRFRYTYYDE-SQGEIYRSIEHLDKMGMGIIEQLDPISFSNYL 
Drosophila MDPTNLFVISSDFCHWGHRFSYTYYDS-SCGAIHKSIEKLDKQGMDIIESLNPHSFTEYL 
C. elegans  EDPRNLFVISSDFCHWGERFSFSPYDRHSSIPIYEQITNMDKQGMSAIETLNPAAFNDYL 
 
Cons   ** ***::*.******.** :: **  *   *:..* ::** **. ** *:* :*.:** 
 
 
Human     KKYHNTICGRHPIGVLLNAITELQ-KNGMN-MSFSFLNYAQSSQCRNWQDSSVSYAAGAL 
Mouse   KKYHNTICGRHPIGVLLNAITELQ-KNGMN-MSFSFLNYAQSSQCRSWQDSSVSYAAGAL 
Zebrafish KKYHNTICGRHPIGVLLNAVAELK-KNGID-MNFSFLNYAQSSQCRNWSDSSVSYAAGAL 
Drosophila RKYNNTICGRHPIGVMLGAVKALQ-DQGYDKMSFKFLKYAQSSQCQDIEDSSVSYASGSL 
C. elegans KKTQNTICGRNPILIMLQAAEHFRISNNHT-HEFRFLHYTQSNKVRSSVDSSVSYASGVL 
 
Cons  :* :******:** ::* *   :: .:.    .* **:*:**.: :.  *******:* * 
 
 
Human TVH-- Human:  Q9Y316   
Mouse TVH-- Mouse:  Q91VH6    
Zebrafish IVH-- Zebrafish: AAH44360 
Drosophila VFEM- Drosophila: Q9VG04 
C. elegans FVHPN C. elegans: Q22915 
 
Cons  ..  
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1.2.4. Memo RNA expression in different breast cell lines 
 
 
Memo
GAPDH
 
  1       2      3       4      5       6      7       8      9      10     11 
 
 
 
1 = HB2 human mammary epithelial cells 
2 = MCF10A human mammary epithelial cells 
3 = MCF7 human breast carcinoma cells 
4 = SKBr3 human breast carcinoma cells 
5 = BT474 human breast carcinoma cells 
6 = MDA-MB-231 human breast carcinoma cells 
7 = MDA-MB-361 human breast carcinoma cells 
8 = MDA-MB-453 human breast carcinoma cells 
9 = ZR 7.5.1 human breast carcinoma cells 
10 = T47D human breast carcinoma cells 
11 = SKBr3 RT- 
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1.2.5. RNA master blot analysis of Memo in human tissues (from Lai et 
al.32) 
 
 
 
 
 
The tissue distribution on the blot from left to right (1-8) in order was: 
A: whole brain; amygdala; caudate nucleus; cerebellum; cerebral cortex; frontal lobe; 
hippocampus; medulla oblongata.  
B: occipital pole; putamen; substantia nigra; temporal lobe; thalamus; subthalamic; 
nucleus; spinal cord. 
C: heart; aorta; skeletal muscle; colon; bladder; uterus; prostate; stomach.  
D: testis; ovary; pancreas; pituitary gland; adrenal gland; thyroid gland; salivary 
gland; mammary gland.  
E: kidney; liver; small intestine; spleen; thymus; peripheral leukocyte; lymph node; 
bone marrow 
F: appendix, lung, trachea, placenta.  
G: fetal brain; fetal heart; fetal kidney; fetal liver; fetal spleen; fetal thymus; fetal 
lung.  
H: yeast total RNA; yeast tRNA; E. coli rRNA; E. coli DNA; Poly r(A); human C0t 
DNA; human DNA; human DNA 
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1.2.5. Memo protein levels in different cells lines  
 
            1      2       3       4       5      6      7       8       9      10     11    12     13     14     15      16 
 
 
 
1 = T47D human breast carcinoma cells 
2 = MDA-MB-453 human breast carcinoma cells 
3 = LS174 TRI human colorectal cancer cells 
4 = HeLa human cervical cancer cells 
5 = MCF7 human breast carcinoma cells 
6 = MDA-MB-231 human breast carcinoma cells 
7 = BT-474 human breast carcinoma cells 
8 = DLDI TR7 human colorectal cancer cells 
9 = HB2 human mammary epithelial cells 
10 = Colon26 mouse colon cancer cells 
11 = MKN7 human gastric cancer cells 
12 = DU4476 human breast carcinoma cells 
13 = SKBr3 human breast carcinoma cells 
14 = NOG8 mouse mammary cells 
15 = HC11 mouse epithelial cells 
16 = Mouse embryonic fibroblasts (Mef) 
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Introduction 
 
Extracellular ligands bind to specific receptors on the cell inducing their activation. The 
receptors, upon dimerization become phosphorylated and stimulate intracellular pathways 
leading to cellular responses, such as cell cycle progression, changes in metabolism, 
cytoskeletal architecture, protein trafficking, adhesion and migration, which may involve 
changes in gene expression. Induction of cell motility by multiple growth factors, 
including EGF-related peptides has been linked to different pathways, including the 
mitogen-activated protein kinase (MAPK) pathway or the phosphatidylinositol-3-kinase 
(PI3K) pathway (Pawson, 1995; Schlessinger, 2000; Yarden and Sliwkowski, 2001). 
Activation of these signaling cascades is known to initiate specific transcriptional 
programs in the nucleus, which involve proto-oncogenes such as fos, jun, and myc, 
members of the family of zinc-finger-containing transcription factors that includes Sp1 
and Egr1, signal transducers and activators of transcription (STATs) as well as Ets family 
members. Moreover, the Rho GTPases are known to regulate the expression of the 
transcription factor SRF (serum response factor) via their ability to induce actin 
polymerization (Hill et al., 1995). The coordinated action of two Rho effector targets, 
mDia and Rho kinase, is required to regulate SRF activity by affecting actin dynamics 
(Geneste et al., 2002). There is evidence that the levels of SRF activation correlate with 
the ratio of F-actin (polymerized actin) to G-actin (unpolymerized actin) (Sotiropoulos et 
al., 1999). A recent study has identified the transcription factor MAL as an actin binding 
protein, that functions as an SRF coactivator and whose translocation from the 
cytoplasma to the nucleus depends on its dissociation from actin monomers (Miralles et 
al., 2003). 
Because most of the migration studies look at short-term events, the contribution and 
importance of transcription or translation for cell migration is not very well understood. 
The intention of this study was to investigate the requirement of de novo RNA and 
protein synthesis for the migration of Neu or Neu add-back mutant expressing cells. Our 
results indicate that following HRG stimulation, post-translational events trigger 
moderate levels of migration. Efficient long-term migration requires de novo RNA and 
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protein synthesis, which is in turn dependent on signaling events activated downstream of 
the tyrosines YC and YD.  
 
   
 
Results 
 
We have analyzed HRG-induced cell migration of Neu and NYPD cells, expressing 
respectively, the wild type Neu receptor and the tyrosine-deficient Neu receptor, over a 
time course of 24 hours. Neu cells started to migrate within 2 hours of HRG treatment 
and the number of migrated cells increased up to 24 hours (Figure 1a). After 2 to 3 hours 
of HRG treatment the number of migrated NYPD cells was the same as the number of 
Neu cells. Starting at 4 hours, the migration of NYPD cells increased at a reduced rate in 
comparison to Neu cells, during the 24 hours time course. We have then investigated the 
possibility that efficient, long-term migration requires de novo RNA and protein 
synthesis, using 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole (DRB), an inhibitor of 
RNA polymerase II or cycloheximide (CHX), respectively. Migration of Neu cells upon 
HRG stimulation was strongly decreased in the presence of CHX (Figure 1b) or in the 
presence of DRB (Figure 1b). Likewise, migration of the YC (cells expressing the 
receptor with the tyrosine 1201) and YD (cells expressing the Neu receptor with the 
tyrosine 1227) cells was sensitive to both inhibitors (Figure 1c and data not shown). In 
contrast, migration of NYPD cells as well as YE cells was not affected by CHX or DRB 
treatment (Figure 1c and data not shown). Importantly, these two inhibitors reduced the 
migration rate of the Neu, YC and YD cells to that observed for the NYPD and YE cells 
(Figure 1c). To rule out that decreased migration was due to toxicity of the inhibitors, we 
separately analyzed the proliferation of the cells in the presence of the inhibitors, by 
counting the cells before and after the migration assay (data not shown). No differences 
in cell proliferation were detected between the control and the treated cells, suggesting 
that the doses used and the duration of the treatment are not toxic to the cells. 
Interestingly, the breast carcinoma cells SKBr3 also showed reduced migration upon 
treatment with CHX or DRB (Figure 1d). These results suggest that following HRG 
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stimulation, post-translational events trigger low levels of migration, whereas efficient 
long-term migration is dependent on de novo RNA and protein synthesis. We propose 
that activation of signaling pathways downstream of the YC and YD tyrosines is 
required, for induction of transcription and translation, these processes are deficient in the 
NYPD and YE cells. 
 
 
 
 
 
Figure 1: a, Migration of Neu and NYPD cells in response to HRG was assayed in the 
presence or absence of cycloheximide (CHX). b, Migration in response of HRG of Neu 
cells was measured after 24 hours in the presence or absence of CHX or DRB. c, HRG-
dependent migration of NYPD, YC, YD and YE was tested over 24 hours in the presence 
or absence of CHX. d, SKBr3 cells migration in response to HRG was assayed over 8 
hours in the presence or absence of CHX or DRB. 
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Memo, the new protein that we identified and described in chapter 1 of the results, acts 
downstream of the YD tyrosine and is not involved in early steps of cell migration such 
as lamellipodia formation. In order to investigate the possibility that Memo and induction 
of de novo protein synthesis are acting on the same pathway, we treated cells with 
cycloheximide and/or Memo siRNA. Cycloheximide treatment of YD cells or 
downregulation of Memo using siRNA in YD cells decreased migration to the same 
extent (Figure 2). Moreover, the combination of the two treatments does not have an 
additive effect on YD cell migration (Figure 2), suggesting that Memo requires de novo 
protein synthesis in order to trigger efficient, long-term cell migration.  
 
 
 
Figure 2: Effect of Memo siRNA on migration of YD cells treated with cycloheximide 
(CHX). 
 
Further studies have to be done in order to identify the transcriptional program triggered 
by the signaling pathways, which are induced specifically downstream of the YC or YD 
tyrosines. 
 
 
 
Discussion 
 
Our data demonstrate that de novo RNA and protein synthesis are required for migration 
of Neu, YC and YD cells as well as SKBr3 cells. Interestingly, the low migration levels 
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of NYPD and YE cells are not affected by the treatment with the two inhibitors. 
Migration of these cells depends on the activation of the MAPK and PI3K pathways (see 
figure 4c of results chapter I). In fact, treatment of the cells with a MAPK or a PI3K 
inhibitor further reduces their migration levels and also prevents lamellipodia formation, 
suggesting that activation of the MAPK and PI3K pathways is essential for early stages 
of migration. Probably, NYPD and YE cells are impaired in migration because they are 
not able to activate signaling pathways leading to transcription and translation of key 
genes required for efficient cell motility.  
In the literature there is increasing evidence that stimulation of cells with different growth 
factors leads to transcriptional activation of different genes required for cellular motility. 
In fact, it was shown that the increased migration seen in HRG-stimulated MCF-7 breast 
cancer cells was associated with transcriptional upregulation of the focal adhesion protein 
paxillin (Vadlamudi et al., 1999). Perhaps, increased levels of paxillin promote cell 
motility via regulation of the dynamic disassembly and subsequent reassembly of the 
focal adhesions. Another group provided evidence for a link between EGF signaling, the 
transcription factor AP-1 (activator protein-1) and cell motility (Malliri et al., 1998). 
They propose a model in which a subset of AP-1 target genes provides the molecular 
bridges between growth factor stimulation and activation of Rac and Rho, which in turn 
regulate morphological and motile responses. In addition, it was shown that constitutive 
expression of the transcription factor Fra-1 and Fra-2 increases DNA binding and 
functional activity of AP-1 (Kustikova et al., 1998). Fra-1 expression leads to an increase 
in random cell migration and in invasion. Moreover, other data reveal that the 
transcription of NFAT (nuclear transcription factor of activated T-cells) is induced by 
integrin clustering in the presence of chemoattractants, resulting in enhanced cell motility 
(Jauliac et al., 2002). 
We have shown that Memo binds to the phosphorylated YD and mediates migration by 
controlling the microtubule cytoskeleton outgrowth. Moreover, we also found that 
migration downstream of Neu, YC and YD cells is dependent on de novo protein 
synthesis. Interestingly, the NYPD cells are able to extend the microtubule network to the 
cell periphery upon HRG treatment, but the low level of migration of these cells is not 
dependent on de novo protein synthesis. Thus, we propose the hypothesis that both 
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microtubule outgrowth and synthesis of new proteins are required for cell motility. This 
proposition is supported by the fact that microtubules can act as tracks along which 
molecular motors transport their cargo molecules (Schliwa and Woehlke, 2003). 
Moreover, microtubules together with microtubule-associated proteins are required for 
ER-to-Golgi (Presley et al., 1997), as well as for Golgi-to-plasma membrane (Kreitzer et 
al., 2000) transport of secretory and plasma membrane proteins. Therefore, we can 
speculate that microtubules transport the newly synthesized proteins to the cell leading 
edge, triggering, as a result, efficient cell motility. 
Further studies have to be performed in order to identify which are the molecules 
required for efficient cell migration and to better understand the role of Memo and 
microtubules in the migratory process. 
 
 
 
Additional materials and methods 
 
Cell migration was tested using 8 µm-pore polycarbonate membrane Transwell chambers 
(Corning Costar Products, Acton, MA, USA) as described in chapter 1. In these 
experiments, cells were pre-incubated for 60 minutes with cycloheximide (10 µg/ml; 
from Sigma, St. Louis, MI, USA) or 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole (20 
µg/ml; from Fluka Chemie GmbH, Buchs, Switzerland). After the plating of the cells 
with medium with or without HRG, the cells were allowed to migrate in the presence of 
the inhibitors for different times before counting. 
For cell proliferation same number of cells were plated and treated with or without the 
inhibitors. The following day, cells were trypsinized and counted using a hemocytometer.  
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V. DISCUSSION 
 
 
Upon ligand binding, ErbB receptors form homo- and heterodimers triggering 
autophosphorylation on specific tyrosine residues in their cytoplasmic tail. These 
phosphorylated tyrosines provide docking sites for intracellular signaling molecules 
containing SH2 and PTB domains and consequently, signaling pathways are activated. 
The ability of the activated receptors to induce proliferation, migration, differentiation or 
transformation is dependent on the receptors’ intrinsic pattern of phosphorylatable 
carboxyterminal tyrosines. In order to identify the signaling pathways involved in 
Neu/ErbB2-dependent cell migration, we generated stable T47D breast carcinoma cell 
lines expressing Neu mutants. This was accomplished by functionally inhibiting the 
endogenous ErbB2 receptor using the human ErbB2-specific single chain antibody scFv-
5R (Beerli et al., 1994). Then, ErbB2 was substituted with wild type Neu, the rat 
homologue of ErbB2, or with Neu mutants harboring none (NYPD) or only one of the 
five major autophosphorylation sites (YA to YE) (Dankort et al., 1997). Using these cell 
lines, we were able to show that cell migration depends on the collaboration of different 
signaling pathways. In fact, the Ras/MAPK, PI3K, p38MAPK and Src-mediated 
signaling pathways are all required for lamellipodia formation, an early step in the 
migration process. Interestingly, we provide evidence that in the context of the 
Neu/ErbB2 receptor, the tyrosines 1201 or 1227 are necessary for breast carcinoma cell 
migration. In the absence of the signaling pathways activated downstream of these two 
tyrosines, cells display only modest motility. 
We performed affinity purification experiments in order to identify by mass spectrometry 
the signaling molecules interacting with the ErbB2’s tyrosines 1201 and 1227. Using this 
method we discovered a novel mediator of Neu/ErbB2-dependent cell migration: Memo. 
Memo is not involved in cell migration stages linked to remodeling of the actin 
cytoskeleton, such as lamellipodia formation, but is required for outgrowth of the 
microtubule cytoskeleton. Memo interacts specifically with the phospho-tyrosine 1227 
via the adaptor molecule Shc. Interestingly, Shc binds to the tyrosine 1201 as well, but 
Memo is not. The Shc adaptor protein contains both an SH2 and a PTB domain and could 
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therefore interact with the receptor’s phosphorylated tyrosines in different ways (Ricci et 
al., 1995; Dankort et al., 2001; Ravichandran, 2001). Interestingly, the amino acid 
sequence around the tyrosine 1201 is a perfect recognition code (hy-X-N-P-X-pY, where 
hy is an hydrophobic amino acid) for binding of PTB containing proteins (Pawson and 
Scott, 1997; Sudol, 1998), whereas the sequence around Tyr1227 is no recognition code 
for neither PTB nor SH2 containing proteins (Songyang et al., 1993). It is possible that 
Shc adopts different conformations upon receptor binding, allowing recruitment of Memo 
only when it is bound to Tyr1227. We are currently investigating the domains by which 
Shc interacts with tyrosine 1201 and 1227 respectively and also the regions of Shc and 
Memo, which are involved in the formation of the Shc/Memo complex. 
 
Memo corresponds to the CGI-27/c21orf19-like hypothetical protein, which was 
identified by comparative genome identification using the C. elegans proteome as 
scaffold (Lai et al., 2000). Memo is very well conserved throughout evolution; in fact 
Memo homologues exist in yeast, nematodes, drosophila and mammals. The sequence of 
Memo does not provide any information about the protein function, since it does not 
contain any characterized domain. We found that Memo is required for the extension of 
microtubules to the periphery. We took advantage of the fact that Memo is conserved in 
yeast, to get a hint of its function. A close look at the proteome of S. cerevisiae provided 
evidence that the S. cerevisiae Memo homologue (Accession Number YJR008w) 
interacts with the Arp1 protein (actin-related protein 1), also called centractin. Arp1 is the 
most abundant component of the dynactin (dynein activator) complex (Schroer, 1994; 
Karki et al., 2000). Another member of the complex is the cytoplasmic dynein, a motor 
protein which transport the cargoes along the microtubules (Schliwa and Woehlke, 2003). 
The functional interaction between cytoplasmic dynein and dynactin is critical for distinct 
cellular processes such as vesicle transport, mitotic spindle assembly and orientation 
(Echeverri et al., 1996; Roghi and Allan, 1999). Moreover, cytoplasmic dynein has been 
implicated in the interactions between microtubules and the cell cortex in different 
physiological contexts, e.g. microtubule cytoskeletal reorientation during wound healing 
(Etienne-Manneville and Hall, 2001; Palazzo et al., 2001). Interestingly, cytoplasmic 
dynein and dynactin subunits have been found associated with the growing microtubule 
 111
plus end and colocalize with CLIP-170 (Vaughan et al., 1999; Xiang et al., 2000). CLIP-
170 is a linker between membranes and microtubules and it stabilizes the microtubules 
during their growing phase (Howard and Hyman, 2003). These studies could help to 
explain the phenotype of the Memo knockdown cells. In fact, we found that these cells 
are impaired in migration, probably because of disrupted microtubule outgrowth and we 
speculate this lead to inefficient transport of the newly synthesized proteins to the cell 
leading edge. The dynactin complex, but also the kinesin are required for the ER-to-Golgi 
and the Golgi-to-plasma membrane transport of the secretory and the plasma membrane 
proteins (Presley et al., 1997; Kreitzer et al., 2000). However, one requirement for these 
molecular motors to work is an intact microtubule cytoskeleton, a structure that is 
disrupted in Memo knockdown cells. Moreover, Memo could play a role in the 
stabilization of the growing microtubules and a possible interaction with plus-end binding 
proteins such as CLIP-170 or with dynactin needs to be investigated. Interestingly, Memo 
is not involved in the control of the stable central microtubule network since 
downregulation of Memo expression in the cells does not disrupt this microtubule 
population. Microtubules, together with multiple mitotic motors are important during cell 
division, for processes such as mitotic spindle assembly and orientation or chromosome 
segregation (Scholey et al., 2003). Proliferation of breast carcinoma cells is not affected 
by Memo downregulation, probably because the central microtubule network is present in 
the Memo knock down cells. Therefore, it seems that cell division is not dependent on 
Memo, even though the dynactin complex plays crucial roles in this process. 
 
Cell migration plays important role in the development and maintenance of multicellular 
organisms.  Cell motility during development is fundamental to the establishment of the 
embryonic architecture, which depends on processes such as gastrulation, neural crest 
formation and also morphogenetic movements that shape the embryo (Locascio and 
Nieto, 2001; Franz et al., 2002). Our studies provide evidence that Memo is required for 
cell migration and therefore it could play a role during development. Moreover, results 
from different experiments show that Memo RNA and protein is expressed in human and 
mouse tissues as well as cell lines. However, nothing is known about the expression 
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pattern of Memo during development. Therefore, some experiments could be done in 
order to identify the expression of Memo during the different developmental stages.  
The ErbB receptors are important during development and targeted inactivation of 
components of the ErbB signaling network highlighted the importance of the receptor-
ligand interactions especially in mid-gestation inductive processes. Apparently, the ErbB 
network is primarily involved in mesenchyme-epithelial crosstalk and in neuronal effects 
on target cells, including muscle, astroglia, oligodendrocytes and Schwann cells (Britsch 
et al., 1998; Buonanno and Fischbach, 2001). NRG-1 is synthesized by mesenchymal or 
neuronal cells, which influence the differentiation, proliferation and migration of adjacent 
epithelial or non-neuronal cells, respectively. Evidence for the essential role of ErbB 
receptors in mid-gestation was provided by the embryonic lethality of ErbB2-, ErbB4- 
and NRG-1-deficient mice at around day 10 post-fertilization due to aberrant cardiac 
development (Gassmann et al., 1995; Lee et al., 1995; Meyer and Birchmeier, 1995). In 
addition to cardiac disorders, ErbB4 deficient mice displayed severe defects in the 
development of the cranial sensory ganglia due to aberrant migration of some neural crest 
cells and aberrant axon pathfinding into the adjacent mesenchyme. Moreover, it was 
shown that migration of neural crest cells to the mesenchyme lateral of the dorsal aorta, 
in which they differentiate into sympathetic neurons, depends on NRG-1, ErbB2 and 
ErbB3 (Britsch et al., 1998). All these data provide some evidence of the importance of 
the ErbB receptors and migration in development. It would be interesting to study the 
role of Memo during development, in order to understand in which developmental steps 
Memo is required.  
The ErbB receptors play central roles during mammary gland development, process 
dependent on cell proliferation, migration, differentiation and apoptosis. Data from 
transgenic mice reveal that ErbB1 KO mice have a normal mammary gland ductal tree at 
birth (Wiesen et al., 1999). A fraction of the ErbB1 KO mice survive after birth and this 
made it possible to determine that these mice, in the puberty have a reduced proliferation 
of mammary epithelium and stroma and a loss of periductal fibroblasts (Wiesen et al., 
1999). Moreover, the mammary tree of MHC (myosin heavy chain)-ErbB2-rescued 
ErbB2 KO animals is normal prior to birth (Stern, 2003). Mammary ductal development 
of the cardiac-rescued MHC-ErbB4 ErbB4 KO is also normal at birth, but during 
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pregnancy the mammary lobuloalveoli fail to differentiate correctly (Tidcombe et al., 
2003). We showed using breast carcinoma cells that Memo is required for cell motility, 
but not for cell proliferation. Therefore some experiments could be done to investigate 
the role of Memo during mammary gland development, especially during the invasion of 
the mammary epithelium into the mammary fat pad, where migration is required.  
Tumorigenesis is a multistep process and occurs as the result of uncontrolled cell 
division, contributing to initial tumor formation, which is followed by metastatic spread. 
The process of metastasis involves an intricate interplay between cell proliferation, 
adhesion, proteolysis, migration and angiogenesis. As cancer cells become metastatic, 
they activate signaling cascades that regulate gene expression, cytoskeletal 
reorganization, cell adhesion and survival (Fidler and Kripke, 1977; Poste and Fidler, 
1980; Kang et al., 2003). These changes allow them to become more invasive and 
migratory and to better survive in different microenvironments. Breast carcinoma cells 
metastasize often to bone and to visceral organs (Thomas et al., 1979; Price and Zhang, 
1990; Boyce et al., 1999; Yoneda et al., 2000; Liotta, 2001; Mundy, 2002). The human 
breast carcinoma cell line MDA-MB-231 is particularly appealing to explore Memo’s 
role in metastasis formation. The orthotopic metastasis model closely resembles the 
situation in breast carcinoma patients. In this model the human mammary tumor cells 
MDA-MB-231 are injected into the inguinal mammary fat pad of SCID (severe combined 
immunodeficiency) mice (Singh et al., 1997; Muller et al., 2001). The mammary cancer 
cells form tumors 7-10 days after injection and subsequently they develop bone and 
visceral metastasis 3-4 weeks after inoculation. Using this model it would be possible to 
study the role of Memo in the early steps of breast tumor formation and even more 
interesting, due to crucial role of Memo in migration, during the whole metastatic 
process. We showed that Memo is required for MDA-MB-231 cell migration, but not for 
proliferation in vitro. Using this model, it would be possible to verify the role of Memo 
for cell proliferation in vivo. In fact, tumor growth is dependent on cell division and in 
the animals it would be possible to measure the size of the mammary tumor, which reflect 
cell proliferation. In another model, the experimental bone metastasis model, the cells are 
directly introduced into the arterial circulation through the left ventricle of the heart in 
young female nude mice (Yoneda et al., 1994; Sung et al., 1997; Kang et al., 2003). The 
 114
carcinoma cells develop radiologically distinctive osteolytic bone metastasis 3-4 weeks 
after cell inoculation. This model is suitable to specifically study the events involved in 
the formation of bone metastasis. However, it has the disadvantage that it lacks the 
critical early steps occurring between tumor formation at the primary site and entry into 
the blood stream. Moreover, visceral organ metastases, which most patients already have 
developed at the time of detection of bone metastasis, are rarely formed. In this model, 
the cells in order to metastasize have to reach the bone via the blood circulation and 
ultimately to arrest in the capillary bed in bone. Afterward, they have to extravasate and 
to destroy the bone in order to form metastases. Extravasation is a process dependent on 
specific adhesion of the tumor cells to the blood vessel endothelial cells and on the 
subsequently migration of the cancer cells between the endothelial cells. Results from our 
experiments reveal that Memo is required for MDA-MB-231 cell migration. Therefore, 
this model appears to be appropriate for investigate the role of the Memo for migration 
during the bone metastasis process.  
 
 
In summary, some more work needs to be done to better comprehend the contribution of 
Memo during the cell migratory process. Moreover, the use of animal models could help 
to improve the knowledge regarding the function of Memo not only during tumor and 
metastases formation, but also during the animal developmental phases. 
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VI. ABBREVIATIONS 
 
+TIP Plus-end-binding protein  
ADAM A Disintegrin-like and metalloproteinase-containing protein 
ADF Actin-depolymerization factor 
AP-1 Activator protein-1 
APC Adenomatous polyposis coli 
AR Amphiregulin 
ARIA Acetylcholine receptor-inducing activity 
Arp Actin-related protein   
BTC Betacellulin 
CHX Cycloheximide 
CLASP CLIP associated protein 
DN Dominant negative 
DRB 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole 
ECM Extracellular matrix 
EGF(R) Epidermal growth factor (receptor) 
EPR Epiregulin 
ER Endoplasmic reticulum 
FAK Focal adhesion kinase 
FGF Fibroblast growth factor 
GAP GTPase-activating protein 
GDI Guanine nucleotide dissociation inhibitor 
GEF Guanine nucleotide exchange factor 
GGF Glial growth factor 
GPCR G-protein coupled receptor 
HB-EGF Heparin-binding EGF 
HRG Heregulin 
MAPK Mitogen-activated protein kinase 
MCAK Mitotic centromere-associated kinesin 
MHC Myosin heavy chain 
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MLC(K) Myosin light chain (kinase) 
MMP Matrix metalloproteinase 
MMTV Mouse mammary tumor virus 
MTOC Microtubule-organizing center 
NDF Neu differentiation factor 
NRG Neuregulin 
PAI-1 Plasminogen activator inhibitor-1 
PAK p21-activated protein kinase 
PDGF(R) Platelet-derived growth factor (receptor) 
PI3-K Phosphatidylinosithol-3-kinase 
PLCγ Phospholipase Cγ 
PTB Phosphotyrosine-binding 
ROCK Rho-associated kinase 
RTK Receptor tyrosine kinase 
SH2/3 Src-homology 2/3 
STAT signal transducers and activators of transcription 
TGF-α Transforming growth factor-α 
Tyr Tyrosine 
uPA Urokinase-type plasminogen activator 
VEGF Vascular endothelial growth factor 
Curriculum Vitae 
 
 
Name  Romina Marone 
Date of birth  December 26, 1976  
Place of birth  Bern 
Nationality  Swiss 
Marital status Single 
 
Working address Friedrich Miescher Institute for Biomedical Research 
   Maulbeerstrasse 66 
   4058 Basel 
   Switzerland 
   Phone: +41 61 697 80 89 
   Fax: +41 61 697 39 76 
   email: romina@fmi.ch 
 
Private address An der hohlen Gasse 12 
   4058 Basel 
   Switzerland 
   Phone: +41 61 681 51 69 
 
Educational record Sept. 1991- June 1995:  High school in Bellinzona (Tessin). 
 Final exam: federal matura, type C 
 Oct. 1995 - Apr. 2000: Student in Biology at the ETH of Zurich. 
 Oct. 1999 - Apr. 2000: Practical part of the diploma thesis in Prof. 
Dr M. Fussenegger’s lab, ETH of Zurich. 
 Jun. 2000 – Mar. 2004: Ph.D. in Prof. Dr. N. E. Hynes’ lab, 
Friedrich Miescher Institute, Basel. 
 
External fundings Sept. 2001- Mar. 2004   Krebsliga Schweiz 
 
Languages Italian (mother language), German, English, French 
 
 122
Publication list 
• Kaufmann H, Marone R, Olayioye M.A., Bailey J.E., Fussenegger M. 
Characterization of an N-terminally truncated cyclin A isoform in mammalian 
cells. J Biol Chem. 276, 29987-93 (2001). 
 
• Kaufmann H, Mazur X, Marone R, Bailey J.E., Fussenegger M. Comparative 
analysis of two controlled proliferation strategies regarding product quality, 
influence on tetracycline-regulated gene expression, and productivity. Biotechnol 
Bioeng. 72, 592-602 (2001). 
 
• Marone R, Hess D, Dankort D, Muller W.J., Hynes N.E., Badache A. Memo is a 
novel mediator of ErbB2-driven cell motility. 
 Manuscript resubmitted to Nature Cell Biology. 
 
 
 
 
 
Meetings 
 
• 10 March 2001: oral presentation at the USGEB Young Investigator Meeting, 
Lausanne, Switzerland 
 
• 27-28 September 2001: Swiss Cell Cycle workshop, Vue-des-Alpes, Switzerland 
 
• 7-9 March 2002: Poster presentation at the USGEB Annual Meeting, Lugano, 
Switzerland 
 
• 29 June- 3 July 2002: Poster presentation at ELSO Meeting, Nice, France 
 
 
• 2-5 May 2003: Poster presentation at the EMBO Workshop Mechanism of Cell 
Migration, Heidelberg, Germany 
 
• 7 May 2003: oral presentation at the SPO (Schwer Punkt Onkologie) Symposium, 
Augst, Switzerland  
 
• 13-17 December 2003: Poster presentation at the ASCB meeting in San 
Francisco, USA  
 
 
 123
 124
Awards 
 
• 10 March 2001: prize for the best USGEB abstract at the USGEB Young 
Investigator Meeting, Lausanne, Switzerland 
 
 
• 15 November 2002: prize for the best poster at the Swiss Society for Oncology 
Annual Meeting, Lausanne, Switzerland 
 
• 26 March 2004: prize ASRIB-Roche 2003, Lugano, Switzerland 
 
